

8-2010

Controlling Reductive Elimination From Novel I(III) Salts Using a SECURE Method

Joseph W. Graskemper

University of Nebraska at Lincoln, jgraskemper@huskers.unl.edu

Follow this and additional works at: <http://digitalcommons.unl.edu/chemistrydiss>



Part of the [Organic Chemistry Commons](#)

Graskemper, Joseph W., "Controlling Reductive Elimination From Novel I(III) Salts Using a SECURE Method" (2010). *Student Research Projects, Dissertations, and Theses - Chemistry Department*. 6.
<http://digitalcommons.unl.edu/chemistrydiss/6>

This Article is brought to you for free and open access by the Chemistry, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Student Research Projects, Dissertations, and Theses - Chemistry Department by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

CONTROLLING REDUCTIVE ELIMINATION
FROM NOVEL I(III) SALTS USING A SECURE METHOD

by

Joseph W. Graskemper

A THESIS

Presented to the Faculty of
The Graduate College in the University of Nebraska
In Partial Fulfillment of Requirements
For the Degree of Master of Science

Major: Chemistry

Under the Supervision of Professor Stephen G. DiMagno

Lincoln, Nebraska

August, 2010

CONTROLLING REDUCTIVE ELIMINATION
FROM NOVEL I(III) SALTS USING A SECURE METHOD

Joseph W. Graskemper, M.S.

University of Nebraska, 2010

Advisor: Stephen G. DiMagno

Positron Emission Tomography (PET) is a valuable clinical, research, and diagnostic technique for human and animal organ imaging. The current market for PET in the United States is \$500 million per year and is projected to be \$5.4 billion per year globally by 2015. To synthesize labeled radiotracers, we are most interested in using ^{18}F as the isotope of choice because it is a nearly ideal positron emitting radionuclide.

Electron-rich aromatic substrates can be particularly difficult to fluorinate. We show that reductive elimination of I(III) diaryliodonium salts provide increased fluorination of electron-rich aromatic substrates. Modest yields of fluorinated product were initially observed due to the lack of regioselectivity in the reductive elimination process. It seemed clear that a better directing group would be needed if extremely electron-rich rings are to be fluorinated in high chemical (or radiochemical) yields using diaryliodonium salts. The use of [2.2]paracyclophane as a directing ligand has been shown by computational and experimental data to provide an increase in steric demand above the plane of the aromatic ring; therefore, destabilizing a reductive elimination transition state. This effect is sufficiently large to provide stereoelectronic control of unidirectional reductive elimination (SECURE) for most nucleophiles; however, benzyne

chemistry was observed when fluorine and 2,2,2-trifluoroethoxide were used as nucleophiles.

To address the benzyne issue, we have shown that the choice of a judiciously substituted cyclophane substituent on I(III) can provide perfect regioselectivity for reductive elimination of iodocyclophanes and fluorination of electron-rich arenes. This work constitutes the first example of regiospecific fluorination of electron-rich aromatic rings using diaryliodonium fluorides. We believe this discovery paves the way for the synthesis of highly elaborated radiotracers from Ar_2IF salts.

Acknowledgements

First and foremost, I want to thank Dr. DiMagno for his enormous amount of support and dedication to my development as a chemist, for without his superb guidance this would have never been possible. I feel extremely lucky to have found such a wonderful advisor to work for, and I most certainly will look back at the times in lab with much enjoyment. I am also thankful to have been a teammate of Dr. DiMagno, or “Skywalker” on the basketball court, it was a good run. I would like to thank the members of the DiMagno group who I have had the pleasure of sharing the past couple years with: Kiel Neumann, Sara Hitchcock, Linlin Qin, Bijia Wang, Jason Kempinger, and Harsha Uppaluri. I am also thankful for having such a great friend in Kiel, we have had many great times (sometimes too great).

I am extremely thankful to my family (Mom, Dad, Dede, Gena, Paige) for all the unending love and support. I honestly do not know where I would be without you all. I would like to thank my dog, Dillinger, for getting me up every morning for the past six months and putting a smile on my face. Finally, to the person who was here by my side through the best and the worst, my incredible loving partner, Allie Salfity. You came out to Nebraska solely to support me in my venture for my degree; words cannot describe how thankful I am to have you in my life.

Table of Contents

ABSTRACT	ii
ACKNOWLEDGEMENTS	iv
TABLE OF CONTENTS	v
LIST OF TABLES	vii
LIST OF FIGURES	viii
LIST OF SCHEMES	ix
<u>CHAPTER ONE</u> – Introduction	11
1.1 Background.....	11
1.2 Fluorination via reductive elimination using diaryliodonium salts.....	16
1.3 References.....	23
<u>CHAPTER TWO</u> – The First I(III) Cyclophanes	24
2.1 Regiospecific reductive elimination from diaryliodonium salts.....	24
2.2 References.....	38
<u>CHAPTER THREE</u> - Regiospecific Fluorination of Electron-Rich Arenes	40
3.1 A solution to observed benzyne chemistry.....	40
3.2 Conclusion.....	42

3.3 References.....	44
<u>EXPERIMENTAL PROCEDURES</u>	45
<u>APPENDIX A – Abbreviations</u>	62
<u>APPENDIX B – NMR Spectra</u>	63

LIST OF TABLES

Table 1-1 List of commonly used positron emitters.....	11
Table 1-2 Observed yields of ArF from the decomposition of 1-8.....	19
Table 2-1 Yields of reductive elimination products from the I(III) salts shown in Scheme 2-4.....	33

LIST OF FIGURES

Figure 1-1 Generation of ^{18}F	12
Figure 1-2 Examples of PET radiotracers.....	13
Figure 1-3 Structure of Kryptofix 222 KF.....	13
Figure 1-4 Iodine as a transition metal ion.....	16

LIST OF SCHEMES

Scheme 1-1 Pd-catalyzed aromatic fluorination utilizing tBuBrettPhos as the ligand...	15
Scheme 1-2 One-step methods to n.c.a. 1-bromo-4-[18F]fluorobenzene.....	17
Scheme 1-3 List of diaryliodonium fluorides made and studied.....	19
Scheme 1-4 Fluorination of drug candidates.....	21
Scheme 2-1 Examples of regioselectivities obtained in thermal decomposition reactions of unsymmetrical diaryliodonium salts.....	25
Scheme 2-2 Regiochemically controlled reductive elimination of an electron-rich, cyclophane-derived diaryliodonium salt.....	27
Scheme 2-3 Calculated TS structures and activation barriers for (2,5-dimethylphenyl) and [2.2]paracyclophan-4-yl iodonium salts.....	29
Scheme 2-4 Functionalization of diaryliodonium salts. (Reductively eliminated aryl iodides are omitted for clarity.).....	31
Scheme 2-5 Synthesis of 2-5.....	34
Scheme 2-6 Anisole functionalization by thermal decomposition of 2-5 in CD ₃ CN.....	35
Scheme 3-1 Observed products and proposed mechanistic benzyne pathway.....	40
Scheme 3-2 Synthesis of 3-1.....	41

Scheme 3-3 Reductive elimination from the iodonium fluoride of 3-1..... 42

CHAPTER ONE

Introduction

1.1 Background

Positron Emission Tomography (PET) is a valuable clinical, research, and diagnostic technique for human and animal organ imaging. The current market for PET in the United States is \$500 million per year and is projected to be \$5.4 billion per year globally by 2015.¹ The imaging process of PET begins when a labeled radioactive tracer is injected into a patient. The ^{18}F nucleus in the radioactive tracer undergoes radioactive decay ($p^+ \rightarrow n + B^+$) and emits a positron. This emitted positron collides with an electron in the environment resulting in an annihilation event. The destruction of matter results in the production of gamma radiation. The gamma radiation is then picked up by spatially addressable scintillation detectors surrounding the patient, and an image is then

Table 1-1 List of commonly used position emitters

Isotope	Half-life	Decay mode	$E_{\beta^+ \text{ avg.}}$ [keV]	Maximum (average) range in tissue [mm]	Maximum specific activity [GBq μmol^{-1}]
^{11}C	20.39 min	β^+ (99.8%) EC (0.24%)	385	3.8 (1)	3.4×10^5
^{13}N	9.965 min	β^+ (99.8%) EC (0.2%)	491	5 (1.5)	7.0×10^5
^{15}O	122.24 s	β^+ (99.9%) EC (0.01%)	735	7.6 (2.7)	3.4×10^6
^{18}F	109.77 min	β^+ (96.73%) EC (3.3%)	242	2.2 (0.3)	6.3×10^4
^{68}Ga	67.629 min	β^+ (89.1%) EC (11.0%)	740	13.6 (3.7)	1.0×10^5
^{124}I	4.1760 d	β^+ (22.8%) EC (11.0%), e^-	188	9.7 (3)	1.2×10^3

Table. Nuclear properties of commonly used positron emitters. (Data taken from Browne and Firestone 1986 and from Brookhaven National Laboratory internet data base, BNL 2003.)

reconstructed on a computer screen of a targeted area or organ.

Commonly used positron emitters include ^{11}C , ^{13}N , ^{15}O , ^{18}F , ^{68}Ga , and ^{124}I (Table 1-1). We are most interested in ^{18}F because it is a nearly ideal positron emitting radionuclide. Attractive characteristics of ^{18}F include: 1) It has a relatively long half life (109.77 min.), which allows ample time for the synthesis and transfer of radiotracers from a cyclotron facility to PET imaging centers. 2) The positron is emitted with relatively low kinetic energy (242 keV) and short range in tissue, and thus is captured proximal to the decay event. This leads to relatively high resolution (1 min.) 3) ^{18}F can be produced in large amounts in a single cyclotron run (>10 Ci). 4) Radiochemical yields for ^{18}F PET tracers can be extremely high.




Figure 1-1 Generation of ^{18}F

^{18}F is generated in a particle accelerator (Figure 1-1). The most effective generation route of ^{18}F is through bombardment of H_2^{18}O with protons from the cyclotron. Once ^{18}F is generated, it is captured on an ion-exchange column, and liberated from the column with a salt solution, such as tetramethylammonium hydroxide (TMAOH), and a nucleophilic fluoride source tetramethylammonium fluoride (TMAF) is obtained. This TMA^{18}F can now be introduced to a tracer of interest.




Figure 1-2 Examples of PET radiotracers

The most widely used ^{18}F PET radiotracer is 2- ^{18}F Fluoro-2-deoxy-D-glucose ([^{18}F]FDG). It is widely used because of its ability to be produced in high yields and shorter reaction times. [^{18}F]FDG is synthesized by nucleophilic fluorination using mannose triflate as a precursor and Kryptofix 222 KF (Figure 1-3) or tetrabutylammonium salts (TBA). There are drawbacks to using [^{18}F]FDG as well. [^{18}F]FDG is rather widely distributed in the body, so identification of exceptionally metabolizing active tissues can be a problem. To address this issue, many different radiotracers need to be efficiently synthesized in order to target specific areas of interest throughout the body. A large number of these desired radiotracers require fluorination on an aromatic substrate (Figure 1-2).





Figure 1-3 Structure of Kryptofix 222 KF

Two methods to prepare fluorinated aromatic radiotracers with ^{18}F include nucleophilic or electrophilic aromatic substitution. Nucleophilic aromatic fluorination is most commonly carried out with Kryptofix 222 KF or CsF. Nucleophilic fluoride, which has a moderate reactivity and high specific activity, is typically used for fluorination of electron-deficient arenes. Electrophilic fluorine is most commonly introduced through $[^{18}\text{F}]\text{F}_2$, or $[^{18}\text{F}]\text{AcOF}$. Electrophilic fluorine is highly reactive and carrier added (^{19}F present), which results in a low specific activity (amount of gamma radiation produced).

Electron-rich aromatic substrates can be particularly difficult to fluorinate. Nucleophilic fluorination of electron-rich arenes can only be accomplished by inclusion of an activating group that is subsequently removed; these multistep transformations are sometimes inefficient for PET chemistry. Direct fluorination of electron rich aromatic rings with $[^{18}\text{F}]\text{F}_2$ generally yields a mixture of regioisomers. Fluorodemetalation (usually fluorodestannylation) with $[^{18}\text{F}]\text{F}_2$ or $[^{18}\text{F}]\text{AcOF}$ can provide control of regiochemistry, however; metal toxicity is a concern and the fluorinated drug is still produced with relative low specific activity. Our goal is to develop a reliable, low-cost, easy-to-use system for on-demand radiolabeling, with the flexibility to develop new probes.



Scheme 1-1 Pd-catalyzed aromatic fluorination utilizing *t*BuBrettPhos as the ligand

Transition metal catalyzed fluorinations are one potential solution to fluorinate electron-rich aromatic substrates.² Recently, Buchwald and co-workers developed extremely hindered phosphine ligands that permit catalytic fluorination from fluoro-Pd(II) complexes for late stage incorporation of fluoride into electron-rich aromatic substrates (Scheme 1-1).² However, this approach is inefficient for PET applications for a number of reasons. The long reaction time (12 hours) and requirement for excess fluorinating agent (6 equiv. CsF) are clearly incompatible with the demands of radiotracer synthesis. In PET chemistry, the fluorinating agent is available in tiny amounts (10 ng / Curie). Regioisomers were identified as products during Buchwald's Pd-catalyzed fluorination of aryl triflates. Although no definitive explanation was given for the presence of regioisomers, the formation of benzyne was suspected to play a role in the formation of 3-fluoroanisole.


1.2 Fluorination via reductive elimination using diaryliodonium salts

While transition metal catalyzed fluorination appears to be a promising approach, given that the key step in the process for ^{18}F chemistry is a reductive elimination, we thought higher valent metal ions would show more promise. A difficulty with transition metals in high oxidation states is the potential for binding more than one anionic ligand. Since fluoride is generally extremely recalcitrant in reductive eliminations, we investigated stable aryl complexes that bound only one anion. It became clear that the conceptual framework used in the optimization of organometallic reactions is directly applicable to iodine chemistry: I(III) acts as a highly electronegative transition metal ion (Figure 1-4).



Figure 1-4 Iodine as a transition metal ion

There is a key difference in the reactivity of I(III) complexes and the late transition metal ions. While $\text{Ar}_2\text{M}(\text{X})_n$ complexes generally undergo reductive elimination of biaryls, Ar_2IX compounds form Ar-F and Ar-I upon reductive elimination. This different reactivity pattern is a direct consequence of the greater electronegativity of iodine and the tremendously increased stability of Ar-I(I) complexes compared to Ar-M complexes. This different reactivity manifold is a substantial advantage for I(III) chemistry.




Scheme 1-2 One-step methods to n.c.a. 1-bromo-4-[¹⁸F]fluorobenzene.³

Applications using iodine in diaryliodonium salts for fluorination of aromatic substrates has been known since the 1980's.⁴⁻⁶ This synthetic strategy was first introduced to ¹⁸F PET radiotracers by Pike and co-workers in 1995.⁷ Prior to our work, the thermal decomposition reactions were performed exclusively in polar solvents, such as acetonitrile (CH₃CN). An example shown in Scheme 1-2 indicates that reductive elimination of diaryliodonium salts offers a highly competitive method to fluorinate unactivated aromatic compounds; The convenience of a one-step reaction to achieve a high radiochemical yield of product is an added bonus. Six different methods (Scheme 1-

2) to prepare 1-bromo-4-[¹⁸F]fluorobenzene were compared by Ermert and co-workers.³ After comparison, it was concluded that the reductive elimination of the symmetrical diaryliodonium salts was the most efficient, with a radiochemical yields of up to 65 %. The unsymmetrical diaryliodonium salt reductive elimination resulted in lower yields of up to 37 %. This lower yield was attributed to the formation of [¹⁸F]fluorobenzene (30 %). Although the symmetrical diaryliodonium salts offer the highest yields, it can be particularly difficult to synthesize the corresponding symmetrical salt of a desired radiotracer candidate if it is highly functionalized.

Studies have been performed in an effort to optimize fluorination of target compounds via reductive elimination of unsymmetrical diaryliodonium salts. Specifically, Woodcraft and co-workers⁸ and Suzuki and co-workers⁹ have achieved high radiochemical yields of multiple fluorinated aromatic substrates under nucleophilic conditions (Kryptofix 222 KF, Tetrabutylammonium fluoride (TBAF)) in polar solvents (CH₃CN, DMSO). A key conclusion from all fluorination is that the more electron-deficient ring is functionalized predominantly.¹⁰ The explanation for the observed regioselectivity is that negative charge builds on the attacked ring at the transition state, and this charge is best supported on the electron-poor ring.



- 1 Ar = 4-methoxyphenyl
- 2 Ar = 3,4-dimethoxyphenyl
- 3 Ar = 2-methoxyphenyl
- 4 Ar = 2-methyl-4,5-dimethoxyphenyl
- 5 Ar = 2,6-dimethoxyphenyl
- 6 Ar = Ph
- 7 Ar = m-CF₃Ph
- 8 Ar = m-CNPh

Scheme 1-3 List of diaryliodonium fluorides made and studied

Bijia Wang of the DiMugno group prepared a variety of diaryliodonium fluorides (Scheme 1-3). The reductive elimination of these diaryliodonium fluorides in acetonitrile was investigated, and the results of the thermal decomposition studies are included in Table 1-2.

Table 1-2 Observed yields of ArF from the decomposition of 1-8

#	1 eq. TMAPF ₆ present		No salt present	
	CD ₃ CN (ArF + 4FA)	C ₆ D ₆ (ArF + 4FA)	CD ₃ CN (ArF + 4FA)	C ₆ D ₆ (ArF + 4FA)
1	17 (-)	76 (-)	43 (-)	86 (-)
2	3 (2 + 1)	78 (59 + 19)	38 (30 + 8)	91 (77 + 14)
3	3 (2 + 1)	84 (59 + 25)	60 (40 + 20)	72 (49 + 23)
4	3 (2 + 1)	90 (76 + 14)	81 (49 + 32)	90 (78 + 12)
5	3 (1 + 2)	67 (28 + 39)	34 (7 + 27)	70 (32 + 38)
6	4 (3 + 1)	51 (41 + 10)	55 (40 + 15)	77 (57 + 20)
7	33 (33 + 0)	86 (86 + 0)	68 (68 + 0)	95 (85 + 10)
8	0	98 (93 + 5)	78 (78 + 0)	89 (89 + 0)


It was clear from this initial work that the use of polar solvents led to non-productive side reactions of these compounds. In the presence of fluoride, reduction of the I(III) salts to Aryl iodides was observed without generation of fluorinated arenes. Since fluoride is a strong donor for transition metal ions, it was suspected that disproportionation and subsequent redox reactions were the cause of this non-productive decomposition chemistry. To suppress these side reactions, the DiMugno group performed the thermal decomposition reactions in non-polar solvents; this change resulted in drastically improved yields of fluorinated arenes. After successfully optimizing solvent conditions, the effect of “spectator salts” such as tetramethylammonium hexafluorophosphate (TMAPF₆) was investigated by Kiel Neumann. He demonstrated (Table 1-1) that the presence of seemingly innocuous salts has a deleterious effect on the yield of fluorinated arenes isolated from the reaction. By filtering off the salt prior to the decomposition reaction, yields improved. It is worthwhile to note, as seen in previous studies, that fluorination of the more electron-deficient ring occurs selectively and that the reaction rates are faster for those salts bearing electron withdrawing substituents. Regioselectivity is not as high as is desired for some salts when the two rings are similarly electron-rich.

It is worth noting that diaryliodonium salt fluorination reactions can be scaled down for PET chemistry. Because the DiMugno group does not currently have access to ¹⁸F, we have developed a MS-based assay to detect nanogram amounts of product in the presence of a million fold excess of potential substrate, minimizing the conditions for radiotracer synthesis. This technique was sufficiently sensitive to detect and quantify

reproducible 500 femtograms of injected 4-fluoroanisole. This approach is also potentially useful for assessing $^{18}\text{F}/^{19}\text{F}$ ratios immediately after bombardment.

The impact of substrate and fluoride dilution was investigated because radiotracer synthesis is typically conducted in the fluoride concentration range of nM - μM . If only the pure bis(4-methoxyphenyl)iodonium fluoride is present, dilution greatly decreases yield of ArF. However, if a 20,000 fold excess of substrate (bis(4-methoxyphenyl)iodonium trifluoroacetate) is present, yields are reproducibly up to 80 % even if only 5 ng of fluoride is available.

Once the conditions for reductive elimination of diaryliodonium fluorides were optimized, the goal of the research was practical application of this new methodology to fluorinate a clinically-relevant radiotracer candidate (Scheme 1-4).



Scheme 1-4 Fluorination of drug candidates

Using our novel fluorination methodology and diaryliodonium salt precursors, ^{19}F -6-Fluorodopamine was prepared by Linlin Qin, ^{19}F -2-fluoroestradiol by ShriHarsha Uppaluri, 3-fluoro-5-[(2-methyl-1,3-thiazol-4-yl)ethynyl]benzonitrile (F-MTEB)¹¹ by Kiel Neumann, and ^{19}F -6-fluorodihydroxyphenylalanine (F-DOPA)¹² by Bijia Wang and Linlin Qin. Two Boc protecting groups were necessary in order to suppress the reducing

nature of the nitrogen and convenience of cleaving the protecting group. The yields for these fluorinated compounds were 90 %, 42 %, 84 %, and 85 %, respectively. Radiochemical yields for the F-MTEB were identical to chemical yields, fully surpassing previously established ^{18}F -MTEB radiochemical yield benchmarks (3 – 5 %) ¹¹. The F-DOPA radiochemical yield was 30 % for n.c.a. methods, and is still climbing. Both the F-MTEB and F-DOPA reactions are complete within 50 minutes (including separation), which is also optimal for radiochemical tracer synthesis. The ^{19}F -2-fluoroestradiol suffered in yield due to the lack of regioselectivity in the reductive elimination process. These initial results of fluorination of drug candidates are very promising, but it seemed clear that a better directing group is needed if extremely electron-rich rings are to be fluorinated in high chemical (or radiochemical) yield using diaryliodonium salts.

1.3 References







- [1] Global Industry Analyst “Radiopharmaceuticals – A US and European Market Report”
- [2] Watson, D. A.; Su, M.; Teverovskiy, G.; Zhang, Y.; Garcia-Fortanet, J.; Kinzel, T.; Buchwald, S. L. *Science* **2009**, 325 (5948), 1661-1664.
- [3] Ermert, J.; Hocke, C.; Ludwig, T.; Gail, R.; Coenen, H. H., *J. Labelled Compd. Radiopharm.* **2004**, 47 (7), 429-441.
- [4] Grushin, V. V.; Tolstaya, T. P.; Lisichkina, I. N., *Izv. Akad. Nauk SSSR, Ser. Khim.* **1983**, (9), 2165-8.
- [5] Van der Puy, M., *Journal of Fluorine Chemistry* **1982**, 21 (3), 385-92.
- [6] Grushin, V. V.; Kantor, M. M.; Tolstaya, T. P.; Shcherbina, T. M., *Izv. Akad. Nauk SSSR, Ser. Khim.* **1984**, (10), 2332-8.
- [7] Pike, V. W.; Aigbirhio, F. I., *J. Chem. Soc., Chem. Commun.* **1995**, (21), 2215-6.
- [8] Carroll, M. A.; Nairne, J.; Woodcraft, J. L.; *J. Labelled Compd. Radiopharm.*, 50, **2007**, 452-454
- [9] M.-R. Zhang, K. Kumata, K. Suzuki, *Tetrahedron Lett.*, 48, **2007**, 8632-8635
- [10] Yamada, Y.; Kashima, K.; Okawara, M., *Bull. Chem. Soc. Jpn.* **1974**, 47 (12), 3179-80.
- [11] Hamill, T. G.; Krause, S.; Ryan, C.; Bonnefous, C.; Govek, S.; Seiders, J.; Cosford, N.; Roppe, J.; Kamenecka, T.; Patel, S.; Gibson, R.; Danabria, S.; Riffel, K.; Eng, E.; King, C.; Green, M.; Burns, H. *Synapse* **2005**, 56, 205-216.
- [12] Garnett ES, Firnau G, Nahmias C. *Nature*. **1983**, 305, 137-138.

CHAPTER TWO

The First I(III) Cyclophanes

2.1 Regiospecific Reductive Elimination from Diaryliodonium Salts


Diaryliodonium salts are useful precursors for arylation of diverse carbon and heteroatom nucleophiles.^[1-4] In practice, poor regioselectivity for reductive elimination narrows the synthetic scope of diaryliodonium salts (Scheme 2-1). Efficient conversion is best obtained when two identical aryl substituents are on I(III), however, the preparation of symmetrical diaryliodonium salts can be problematic and uneconomical.^[11] For relatively complex aromatic molecules, the tandem synthesis and protection of the oxidized (I(III)) and reduced (organometallic) coupling partners necessary to prepare the symmetrical diaryliodonium salt is often a significant challenge, and purification of the functionalized product from the reductively eliminated aryl iodide can prove difficult.



Scheme 2-1 Examples of regioselectivities obtained in thermal decomposition reactions of unsymmetrical diaryliodonium salts.^[5-10]

In the thermal decomposition of unsymmetrical diaryliodonium salts, the identity of the aryl iodide reductively eliminated is typically dictated by electronic effects; the electron-rich aryl iodide and the functionalized electron-poor aromatic compound are formed predominantly (Scheme 2-1). Selectively functionalized electron-rich aromatic rings are often the desired target compounds, but extremely electron-rich diaryliodonium salts are prone to side reactions involving redox and inner-sphere electron transfer, thus there is a limit to using electronic control to achieve regioselectivity.

We sought a universal “locked” aryl substituent that would result in StereoElectronic Control of Unidirectional Reductive Elimination (*SECURE*) from diaryliodonium salts. Since electronic effects cannot be used exclusively to achieve this end, steric and/or stereoelectronic effects must be exploited to gain regiocontrol of reductive elimination. Here we show that the use of cyclophane-derived iodonium salts permits regiospecific reductive elimination (Scheme 2-2).




Scheme 2-2 Regiochemically controlled reductive elimination of an electron-rich, cyclophane-derived diaryliodonium salt

The impact of steric effects upon reductive elimination in diaryliodonium salts has been investigated in some detail. Aryl methyl substituents ortho to the I(III) center offer a modest acceleration in elimination rates, so that there is a slight preference for the more highly substituted product to be functionalized (Scheme 2-2).^[7, 12] Two potential origins of this “ortho effect” are: 1) the more sterically demanding aromatic ring prefers an equatorial position syn to the nucleophile, and 2) the ortho-substituted aromatic is more likely to prefer a conformation in which the π -system is more likely to align with the incoming nucleophile.^[13-15] In an exception to this rule, Ochiai and coworkers have shown that for binaphthyl aryl iodonium salts, ortho-substitution coupled with sterically demanding enolate nucleophiles results in alkylation of the less hindered ring, though only a small number of electronically similar aryl rings were investigated.^[16] Selective

functionalization of the more electron-rich aromatic ring in an unsymmetrical diaryliodonium salt remains an unsolved problem.

Our approach was to design an aryl ligand on iodine that would generate a highly strained reductive elimination transition state. If the mechanistic assumption of a concerted reductive elimination process is adopted, selective destabilization of this transition state requires significant steric congestion above and/or below the aromatic ring and little steric congestion in the plane of the ring. Thus, “strapped” or “capped” aromatic compounds were the initial leads for investigating *SECURE* methodology. [2.2]Paracyclophane^[17, 18] is a particularly attractive potential iodine(III) ligand because of its commercial availability, its efficient and established functionalization chemistry,^[19] its severe out of plane steric congestion, and the potential to exploit the planar chiral ligand in stereoselective reactions;^[20] however, compounds in which an I(III) center is bonded directly to [2.2]paracyclophane have not been reported to date.




Scheme 2-3 Calculated TS structures and activation barriers for (2,5-dimethylphenyl) and [2.2]paracyclophan-4-yl iodonium salts.

The results of an initial computational study (B3LYP/DGDZVP, ZPE corrected) are shown in Scheme 2-3. We selected azide transfer in diaryliodonium salts for our test reaction since diaryliodonium azides are known to undergo reductive elimination at or near room temperature,^[9, 21] and because the small azide nucleophile has a relatively modest steric demand. Ground and transition state energies were calculated for a highly simplified model of azide substitution, loss of HI from the HIN_3Ar complexes of *p*-xylene and [2.2]paracyclophane. Inspection of Scheme 2-3 shows that movement from the ground state to the transition state geometries for azide substitution is accompanied by ipso carbon rehybridization and deflection of the HI group out of the plane. For the xylyl derivative the C4-C1-I angle is 161.9°. However, in the [2.2]paracyclophan-4-yl transition state structure the significant steric demand of the

second ring in the planar chiral ligand inhibits out of plane movement of the iodine atom (C4-C1-I angle is 167.2°). This structural difference is associated with an energetic penalty; the calculated free energy of activation for reductive elimination of HI from the *p*-xylene salt is 13.7 kcal/mol, while the barrier for the cyclophane derivative is 4.8 kcal/mol higher. Armed with an “in silico” justification for the *SECURE* concept, we sought its empirical validation.

To compare the directing effects of the electronically similar *p*-xylyl and [2.2]paracyclophan-4-yl groups experimentally, we synthesized the appropriate unsymmetrical diaryliodonium salts **1**. 4-Bromo-[2.2]paracyclophane^[19, 22] was lithiated (t-BuLi, Et₂O, -78 °C) and transmetalated with anhydrous zinc chloride. Following removal of the ether solvent, the organozinc chloride reagent was treated with 2,5-dimethyl(diacetoxyiodo)benzene in acetonitrile at -40 °C. After isolation and ion exchange to the hexafluorophosphate salt, compound **1** was formed in 18% yield. (Though organolithium,^[23, 24] organoboron,^[25] organosilicon,^[26] and organotin^[27] compounds have been used for diaryliodonium salt synthesis, to our knowledge this is the first example of the preparation of a diaryliodonium salt from an arylzinc chloride. The unusual reaction conditions used here were required because 4-trialkylstannyl[2.2]paracyclophanes do not transfer the cyclophane moiety cleanly in transmetalation reactions.^[28] A likely explanation for the poor reactivity of the stannane is that the transition state for cyclophane transfer is highly congested and resembles that shown in Scheme 2-3.)



Scheme 2-4 Functionalization of diaryliodonium salts. (Reductively eliminated aryl iodides are omitted for clarity.)

The hexafluorophosphate salt of **2-1** is particularly convenient because a wide range of nucleophiles may be introduced via their tetraalkylammonium or sodium salts. Accordingly, when compound **2-1** was treated with TBAN_3 and heated at 45 °C in CD_3CN (0.04 M), conversion of the diaryliodonium azide was complete within a few hours. In support of the initial hypothesis, the azidoxylene is formed exclusively in excellent yield, and no azidocyclophane is observed at the detection limit of ^1H NMR spectroscopy. This unidirectional elimination is also observed with thiocyanate, phenoxide, thiophenoxide, trifluoroethoxide, and acetate (Table 1). The observed

selectivity (> 99:1) corresponds to a difference in the free energies of activation ($\Delta\Delta G^\ddagger$) of at least 2.8 kcal/mol. Thus, the validity of the computational model is confirmed.

To provide context for the *SECURE* results, arene functionalization by various nucleophiles (X) in compound **2-2** was investigated. The regioselectivity observed during the reductive elimination of cyclophanyl-substituted diaryliodonium salts mirrors that of 4-methoxyphenyl derivatives (Table 2-1). The 4-methoxyphenyl moiety is the most effective, commonly employed directing group in diaryliodonium chemistry^[10, 29, 30], however perfect regioselectivity for arene functionalization is not observed with this directing group. For the redox active thiophenoxide and phenoxide nucleophiles, some loss of regiocontrol is evident and functionalized anisoles are formed.

To test the relative directing group abilities of 4-methoxyphenyl and [2.2]paracyclophan-4-yl substituents, we prepared the unsymmetrical I(III) derivative **2-3** from 4-methoxy(diacetoxyiodo)benzene (38% yield) and examined its thermal decomposition chemistry. More vigorous reaction conditions (80 °C, CD₃CN) were necessary to promote speedy carbon-heteroatom bond formation with acetate and thiocyanate from **2-3** in comparison to **2-1** or **2-2**. As can be seen from inspection of Table 2-1, the directing group ability of the [2.2]paracyclophane ligand is comparable or slightly superior to that of the 4-methoxyphenyl substituent on I(III).

The 2-thienyl substituent has been reported to deliver high regioselectivities for the radiofluorination of various electron-rich arenes,^[31] We synthesized **4** to examine the relative directing group abilities of the 2-thienyl and 4-methoxyphenyl substituents under stoichiometric conditions. Inspection of the data in Table 2-1 indicates that, for the nucleophiles examined here, the 2-thienyl moiety's directing group ability is roughly

comparable to the 4-methoxyphenyl and [2.2]paracyclophane ligands on I(III). In all cases significant amounts of the 4-iodoanisole are generated during the thermal decomposition reactions of **2-4**, even when 2-functionalized thiophenes are not observed. These data support Carroll's assessment^[32] and the original observations by Yamada and Okawara^[33] that the directing group ability of the 2-thienyl and 4-methoxyphenyl substituents are similar.

Table 2-1 Yields^a of reductive elimination products from the I(III) salts shown in Scheme 2-4.


X	2-1		2-2		2-3		2-4	
	2-1a	2-1b	2-2a	2-2b	2-3a	2-3b	2-4a	2-4b
N ₃	99<	0	99<	0	86	14	66	0 ^b
OAc	85	0	99<	0	68	31	18	0 ^b
OPh	87	0	96	4	51	40	69	23
OCH ₂ CF ₃	82	0	80	0	19	39	17	43
SCN	99<	0	99<	0	81	18	43	0 ^b
SPh	98	0	95	5	43	52	30	40

^aAll yields were determined by ¹H NMR spectroscopy and confirmed by GC-MS.

^bDecomposition of the functionalized thiophene was observed.


Though the data in Table 1 are limited, it appears that for oxygen or sulphur nucleophiles the directing group ability of the cyclophane ligand diminishes as nucleophile basicity and the driving force for functionalizing the more electron-poor ring increase. Such a trend is consistent with Hammond's postulate and a concerted, reductive elimination mechanism in which less steric strain is developed at the cyclophane ipso carbon atom as the reaction becomes more exergonic.

The kinetics of aryl azide formation from N_3 salts of **2-1**, **2-2** and **2-3** were investigated to probe the relative steric and electronic contributions to the observed regioselectivity. The observed rate constants for xylyl azide formation (CD_3CN , 45 °C) were $4.2 \times 10^{-4} \text{ s}^{-1}$, $5.5 \times 10^{-5} \text{ s}^{-1}$, and $3.3 \times 10^{-6} \text{ s}^{-1}$, corresponding to free energies of activation of 21.7, 22.9, and 24.6 kcal/mol for the reactions of **2-1**, **2-2** and **2-3**, respectively. The fact that the rate constant for formation of azidoxylene is greater for **1** than **2-2** indicates that 4-iodo-[2.2]paracyclophane is a significantly better leaving group than 4-iodoanisole. Since leaving group ability is correlated with the electron density on iodine in the aryl iodide being reductively eliminated, these kinetic data show experimentally that the [2.2]paracyclophane ligand is a significantly more electron-poor aryl substituent than 4-methoxyphenyl and that steric destabilization of the transition state is responsible for the enhanced directing group ability of the [2.2]paracyclophane ligand.



Scheme 2-5 Synthesis of 2-5. (a. 1. *t*-BuLi, Et₂O, -78 °C, 2. B(OMe)₃, 3. H₂O₂, NaOH, H₂O; b. K₂CO₃, CH₃I, CH₃CN, 80 °C; c. NBS, CH₂Cl₂; d. 1. *t*-BuLi, Et₂O, -78 °C, 2. ZnCl₂; e. 1. 4-MeOC₆H₄I(OAc)₂, CH₃CN, -40 °C, f. NaPF₆, H₂O.)

These initial results validated the *SECURE* concept, but perfect regiochemical control was still not available for functionalizing very electron-rich rings. To address this issue we prepared compound **2-5**, which features an electron donating methoxy substituent para to the I(III) center (Scheme 2-5). The methoxy substituent enhances the solubility of the cyclophane organozinc chloride reagent, leading to improved yield in the I(III) transfer reaction.



Scheme 2-6 Anisole functionalization by thermal decomposition of **2-5** in CD₃CN

We were gratified to find that **2-5** provides excellent regiochemical control for arene functionalization across the range of nucleophiles investigated here. Only anisole substitution was observed after the thermal decomposition of the azide, acetate, phenoxide, thiocyanate, and thiophenoxide salts (Scheme 2-6). However, a mixture of cyclophane- (30%) and anisole-substituted (60%) products was obtained from the reductive elimination of the 2,2,2-trifluoroethoxide salt of **2-5**. The reason for the breakdown in regioselectivity is clear from the product analysis, which shows roughly equal amounts of 3- and 4-(2,2,2-trifluoroethoxy)anisole, as well as roughly equal amounts of the two CF₃CH₂O-substituted cyclophane regioisomers. This lack of selectivity and distribution of regioisomers is consistent with a change in mechanism to one involving benzyne intermediates. For this basic nucleophile, the strategy of raising

the transition state energy for reductive elimination of the aryl iodide enables the benzyne reaction manifold to be competitive.

In summary, computational and experimental data show that an increase in steric demand above the plane of the aromatic ring destabilizes a reductive elimination transition state. This effect is sufficiently large to provide stereoelectronic control of unidirectional reductive elimination (*SECURE*); a number of examples are provided to show that the intrinsic electronic bias in reductive elimination reactions of I(III) compounds can be overcome. Significantly, even 4-methoxyphenyl groups can be functionalized regiospecifically. Moreover, since the approach is a general one, it is anticipated that *SECURE* will be useful for controlling reductive elimination from a variety of high valent main group and transition metal ions.

2.2 References

- [1] E. A. Merritt, B. Olofsson, *Angew. Chem., Int. Ed.* **2009**, *48*, 9052.
- [2] V. V. Zhdankin, P. J. Stang, *Chem. Rev.* **2008**, *108*, 5299.
- [3] T. Wirth, *Angew. Chem., Int. Ed.* **2005**, *44*, 3656.
- [4] T. Wirth, in *Top. Curr. Chem., Vol. 224*, Springer, Berlin, **2003**.
- [5] M. Fujita, E. Mishima, T. Okuyama, *J. Phys. Org. Chem.* **2007**, *20*, 241.
- [6] C. H. Oh, J. S. Kim, H. H. Jung, *J. Org. Chem.* **1999**, *64*, 1338.
- [7] Y. Yamada, M. Okawara, *Bull. Chem. Soc. Jap.* **1972**, *45*, 1860.
- [8] Y. Yamada, K. Kashima, M. Okawara, *Bull. Chem. Soc. Jpn.* **1974**, *47*, 3179.
- [9] J. J. Lubinkowski, M. Gomez, J. L. Calderon, W. E. McEwen, *J. Org. Chem.* **1978**, *43*, 2432.
- [10] A. Shah, V. W. Pike, D. A. Widdowson, *J. Chem. Soc., Perkin Trans. 1* **1998**, 2043.
- [11] L. Cai, S. Lu, V. W. Pike, *Eur. J. Org. Chem.* **2008**, 2853.
- [12] K. M. Lancer, G. H. Wiegand, *J. Org. Chem.* **1976**, *41*, 3360.
- [13] V. V. Grushin, *Acc. Chem. Res.* **1992**, *25*, 529.
- [14] V. V. Grushin, I. I. Demkina, T. P. Tolstaya, *J. Chem. Soc., Perkin Trans. 2* **1992**, 505.
- [15] M. A. Carroll, S. Martin-Santamaria, V. W. Pike, H. S. Rzepa, D. A. Widdowson, *J. Chem. Soc., Perkin Trans. 2* **1999**, 2707.
- [16] M. Ochiai, Y. Kitagawa, N. Takayama, Y. Takaoka, M. Shiro, *J. Am. Chem. Soc.* **1999**, *121*, 9233.
- [17] D. J. Cram, H. Steinberg, *J. Am. Chem. Soc.* **1951**, *73*, 5691.


- [18] C. J. Brown, A. C. Farthing, *Nature (London, U. K.)* **1949**, *164*, 915.
- [19] H. J. Reich, D. J. Cram, *J. Amer. Chem. Soc.* **1969**, *91*, 3534.
- [20] S. E. Gibson, J. D. Knight, *Org. Biomol. Chem.* **2003**, *1*, 1256.
- [21] V. V. Grushin, M. M. Kantor, T. P. Tolstaya, T. M. Shcherbina, *Izv. Akad. Nauk SSSR, Ser. Khim.* **1984**, 2332.
- [22] H. J. Reich, D. J. Cram, *J. Amer. Chem. Soc.* **1968**, *90*, 1365.
- [23] F. M. Beringer, R. A. Nathan, *J. Org. Chem.* **1970**, *35*, 2095.
- [24] F. M. Beringer, L. L. Chang, *J. Org. Chem.* **1972**, *37*, 1516.
- [25] M. A. Carroll, V. W. Pike, D. A. Widdowson, *Tetrahedron Lett.* **2000**, *41*, 5393.
- [26] G. F. Koser, R. H. Wettach, C. S. Smith, *J. Org. Chem.* **1980**, *45*, 1543.
- [27] V. W. Pike, F. Butt, A. Shah, D. A. Widdowson, *J. Chem. Soc., Perkin Trans. 1* **1999**, 245.
- [28] V. A. Nikanorov, V. I. Rozenberg, V. G. Kharitonov, E. V. Yatsenko, V. V. Mikul'shina, N. A. Bumagin, I. P. Beletskaya, V. N. Guryshchev, V. V. Yur'ev, O. A. Reutov, *Metalloorg. Khim.* **1991**, *4*, 689.
- [29] M. A. Carroll, J. Nairne, J. L. Woodcraft, *J. Labelled Compd. Radiopharm.* **2007**, *50*, 452.
- [30] M.-R. Zhang, K. Kumata, K. Suzuki, *Tetrahedron Lett.* **2007**, *48*, 8632.
- [31] T. L. Ross, J. Ermert, C. Hocke, H. H. Coenen, *J. Am. Chem. Soc.* **2007**, *129*, 8018.
- [32] M. A. Carroll, C. Jones, S.-L. Tang, *J. Labelled Compd. Radiopharm.* **2007**, *50*, 450.
- [33] Y. Yamada, M. Okawara, *Bull. Chem. Soc. Jap.* **1972**, *45*, 2515.
- [34] A. R. Katritzky, J. K. Gallos, H. D. Durst, *Magn. Reson. Chem.* **1989**, *27*, 815.
- [35] G. Cerioni, G. Ucheddu, *Tetrahedron Lett.* **2004**, *45*, 505.

CHAPTER THREE

Regiospecific Fluorination of Electron-Rich Arenes


3.1 A solution to observed benzyne chemistry

As stated in 2.1, a mixture of products (cyclophane- (30 %) and anisole-substituted (60 %)) were obtained from reductive elimination of the 2,2,2-trifluoroethoxide salt. This suspected benzyne chemistry was also observed when fluorine was used as the nucleophile. The proposed mechanism that resulted in formation of these products is shown in Scheme 3-1.




Scheme 3-1 Observed products and proposed mechanistic benzyne pathway

We suspected that a cyclophane substituent ortho to the I(III) center would shut down benzyne chemistry on the cyclophane and restore regiospecificity for fluorination. Toward this end, we developed a synthesis of compound **3-1** shown in Scheme 3-2.



Scheme 3-2 Synthesis of 3-1

Our original approach to obtaining **3-1** was through ortho-lithiation of 4-methoxy[2.2]paracyclophane and subsequent transmetalation with zinc chloride. Direct ortho-lithiation of methoxy cyclophane was not successful, even with *t*-BuLi or with *n*-BuLi / tetramethylethyldiamine (TMEDA) mixtures. We suspect that the steric congestion of the cyclophane ring system makes ortho-activation difficult. Thus, we installed a better ortho directing group (carbamate) and planned a more indirect synthesis (Scheme 3-2). This synthesis relied heavily on the work of Hopf¹, Lectka², and Snieckus³ who showed that efficient lithiation was possible with the carbamated directing group. By synthesizing O-(4-[2.2]paracyclophanyl) diethylcarbamate, we were able to obtain the corresponding 4-methoxy-5-iodo[2.2]paracyclophane in 73% yield over four steps. Following our previous synthetic strategy for introducing the iodoaniso moiety into **2-3**, **2-4**, and **2-5**, we were able to obtain **3-1** in 13% yield.



Scheme 3-3 Reductive elimination from the iodonium fluoride of 3-1.

Reductive elimination reactions with the iodonium fluoride of **3-1** were studied (Scheme 3-3). The results demonstrated that by blocking the ortho position with a methoxy group, benzyne chemistry was completely shut down on the cyclophane ring. Using NMR and GC analysis, the 4-fluoroanisole was the major product, and was obtained in 55 % yield. To our surprise, evidence for benzyne chemistry on the anisole ring was almost absent; less than a 1% yield of 3-fluoroanisole was present when the thermal decomposition reaction was conducted at 80°C (Scheme 3-3).

3.2 Conclusion

We have shown that the choice of a judiciously substituted cyclophane substituent on I(III) can provide perfect regioselectivity for reductive elimination of iodocyclophanes and fluorination of electron-rich arenes. This work constitutes the first example of regiospecific fluorination of electron-rich aromatic rings using diaryliodonium fluorides.


We believe this discovery paves the way for the synthesis of highly elaborated radiotracers from Ar_2IF salts.

3.3 References

- 1) Barrett, D.G.; Hopf, H. *Liebigs. Ann.* **1995**, 449-451.
- 2) Wack, H.; France, S.; Hafez, A.; Drury, W.; Weatherwax, A.; Lectka, T. *J. Org. Chem.* **2004**, *69*, 4531.
- 3) Sibi, M. P.; Snieckus, V. *J. Org. Chem.* **1983**, *48*, 1935.

Experimental Procedures


Bis(acetyloxy)-(4-methoxyphenyl)- λ_3 -iodane; (1-(diacetoxyiodo)-4-methoxybenzene)



4-Iodoanisole (2.34 g, 10 mmol) was dissolved in 90 mL of glacial acetic acid and the stirred solution was warmed to 40 °C. Sodium perborate tetrahydrate (13.6 g, 110 mmol) was added in portions over the course of one hour. After the addition was complete, the temperature of the reaction mixture was maintained at 40 °C for 8 h before it was allowed to cool to room temperature. Half of the acetic acid (~ 45 mL) was removed by distillation at reduced pressure. The remaining solution was treated with 100 mL of deionized water and the aqueous layer was extracted (3 × 40 mL) with dichloromethane. The combined organic fractions were dried over sodium sulfate, and the solvent was removed by rotary evaporation to give 2.25 g (64%) of 1-(diacetoxyiodo)-4-methoxybenzene, **1**. This compound was dried in vacuo and used without further purification. ¹H NMR (CD₃CN, 400 MHz, 25 °C): δ 8.055 (d, J = 9.1 Hz, 2H, H2/H6), 7.053 (d, J = 9.1 Hz, 2H, H3/H5), 3.861 (s, 3H, OMe), 1.905 (s, 6H, (OCOCH₃)₂); ¹³C NMR (CD₃CN, 100 MHz, 25 °C) δ 177.73 (CO), 163.73 (C4), 138.75

(C2/C6), 118.00, (C3/C5), 111.97 (C1), 56.85 (OMe), 20.76 ((OCOCH₃)₂); HRMS: (HRFAB) calcd. for C₁₄H₁₃NO₄I [M – 2OAc+3-NBA]⁺ 385.9889 found 385.9885. (lit. ^{2,3} ¹³C NMR (CDCl₃, 50 MHz, 20 °C) δ 162.0 (C4), 137.0 (C2/C6), 116.5 (C3/C5), 111.4 (C1).); ¹³C NMR (CDCl₃, 75 MHz, 25 °C) δ 176.31 (CO), 111.64 (C1), 20.36 ((OCOCH₃)₂).

4-Bromo-[2.2]paracyclophane




N-Bromosuccinimide (890.1 mg, 5.0 mmol) and trifluoroacetic acid (570 mg, 0.385 mL, 5.0 mmol) were dissolved in 40 mL of dichloromethane and added to a CH₂Cl₂ solution (80 mL) of [2.2]paracyclophane (1.0297 g, 4.9 mmol). The resulting mixture was covered from light and stirred for 4 hours at room temperature. The solution was transferred to a separatory funnel and washed (3 x 50 mL) with 2 M aqueous sodium bicarbonate solution followed by a single deionized water wash. The organic layer was separated, dried over Na₂SO₄, and the solvent was evaporated to give a nearly colorless solid (1.061 g, 75%) that was sufficiently pure to carry forward in the synthesis. ¹H NMR (CDCl₃, 400 MHz, 25 °C): δ 7.18 (dd, J = 7.8, 1.9 Hz, 1 H), 6.45-6.61 (m, 6 H), 3.45-3.52 (m, 1 H), 2.80-3.26 (m, 7 H); ¹³C NMR (CDCl₃, 100 MHz, 25 °C) δ 141.61, 139.33,

139.11, 137.25, 135.05, 133.31, 133.02, 132.91, 132.25, 131.46, 128.69, 126.97, 35.85, 35.48, 34.82, 33.47.

Cram, D. J.; Day, A. C. *J. Am. Chem. Soc.* **1966**, *31*, 1227-32.

4-Hydroxy[2.2]paracyclophane




In a 50 mL Schlenk tube under nitrogen, a stirred, cold (-78 °C) solution of 4-bromo[2.2]paracyclophane (4.0 mmol, 1.14 g) in 50 mL of anhydrous diethyl ether was treated with t-BuLi (1.7 M in pentane, 2.5 equiv., added dropwise). The resulting mixture was stirred at -78 °C for 20 minutes and held subsequently at 0 °C for 20 min. To this heterogeneous yellow mixture trimethyl borate (831.29 mg, 8.0 mmol) was added dropwise and the mixture was stirred for 1 hour at room temperature. During this period the solution became homogeneous and dark yellow. Aqueous NaOH (0.5 M, 2 mL) and H₂O₂ (30%, 1.5 mL) were added. There was a slight exotherm and gas was evolved. The resulting mixture was allowed to stir overnight at room temperature. Additional aqueous NaOH solution (0.5 M, 5 mL) was added and the pH of the solution was adjusted to neutral using saturated sodium bicarbonate solution and 1 M HCl. The mixture was extracted (3 x 20 mL) with diethyl ether. The combined ether extracts were washed with 0.5 M sodium bisulfite, separated, and dried over Na₂SO₄. Removal of the solvent by

rotary evaporation gave a light brown solid (844.1 mg, 94.1%). ^1H NMR (CDCl_3 , 400 MHz, 25 °C): δ 7.01 (dd, $J = 7.8, 1.9$ Hz, 1 H), 6.56 (dd, $J = 7.8, 1.9$ Hz, 1 H), 6.46 (dd, $J = 7.8, 1.9$ Hz, 1 H), 6.38-6.42 (m, 2 H), 6.27 (dd, $J = 7.7, 1.6$ Hz, 1 H), 5.55 (d, $J = 1.6$ Hz, 1 H), 3.29-3.39 (m, 1 H), 2.87-3.16 (m, 6 H), 2.62-2.73 (m, 1 H). ^{13}C NMR (CDCl_3 , 100 MHz, 25 °C): δ 153.7, 142.0, 139.6, 138.8, 135.5, 133.0, 132.8, 131.9, 127.9, 125.4, 125.0, 122.6, 35.3, 34.8, 33.8, 31.1.

Krohn, K.; Rieger, H.; Hopf, H.; Barrett, D.; Jones, P. G.; Döring, D. *Chem. Ber.* **1990**, *123* 1729.

4-Methoxy[2.2]paracyclophane




In a 100 mL glass tube sealed with a Teflon screw cap closure, potassium carbonate (1.66 g, 12 mmol) and 4-hydroxy[2.2]paracyclophane (869.6 mg, 3.87 mmol) were heated to 80 °C in 60 mL of acetonitrile for 30 minutes. Iodomethane (1.7 g, 12 mmol) was added to the mixture, the storage tube was sealed, and the stirred solution was heated at 80 °C for 3 days. The solvent was removed by rotary evaporation and the remaining solid was treated with ethyl acetate and water and transferred to a separatory funnel. The aqueous layer was neutralized with 0.1 M HCl solution, the mixture was shaken, and the organic layer was separated and dried over Na_2SO_4 . Rotary evaporation of solvent yielded a nearly colorless solid. The somewhat insoluble material was

dissolved in hot hexanes and purified via column chromatography (silica gel, hexanes, $R_f = 0.28$) to afford a colorless solid (602.4 mg, 65.4%). ^1H NMR (CDCl_3 , 400 MHz, 25 °C): δ 6.76 (dd, $J = 7.8, 1.8$ Hz, 1 H), 6.38 – 6.55 (m, 4 H), 6.28 (dd, $J = 7.5, 1.4$ Hz, 1 H), 5.67 (d, $J = 1.3$, 1 H), 3.71 (s, 3 H), 3.42 – 3.48 (m, 1 H), 2.99 – 3.13 (m, 6 H), 2.59 – 2.66 (m, 1 H). ^{13}C NMR (CDCl_3 , 100 MHz, 25 °C): δ 157.6, 142.1, 140.3, 138.8, 135.0, 133.7, 133.1, 131.5, 128.4, 127.5, 124.4, 116.7, 54.3, 35.5, 35.4, 34.1, 31.7.

Cram, D. J.; Day, A. C. *J. Org. Chem.* **1966**, *31*, 1227-32.

O-(4-[2.2]paracyclophanyl) diethylcarbamate




In a 250 mL Schlenk flask, a solution of 4-hydroxy[2.2]paracyclophane (2.88 mmol, 644.9 mg) in 50 mL of anhydrous toluene was treated with 4-(dimethylamino)pyridine (DMAP) (5.76 mmol, 703.7 mg) and diethylcarbamoyl chloride (5.76 mmol, 0.73 mL). The resulting mixture was stirred at reflux for 7 hours, while the progress of the reaction was monitored by TLC (silica gel, dichloromethane). The reaction was cooled to room temperature, hydrolyzed with 50 mL of deionized water, and extracted (3 x 35 mL) with dichloromethane. The combined organic extracts were dried over Na_2SO_4 . The solvent was removed by rotary evaporation, and the raw product was purified by column chromatography (silica gel, dichloromethane) to afford a white

crystalline solid (698.9 mg, 75%). ^1H NMR (CDCl_3 , 400 MHz, 25 °C): δ 6.85 (dd, $J = 7.8, 1.3$ Hz, 1 H), 6.41-6.57 (m, 5 H), 6.12 (d, $J = 1.3$ Hz, 1 H), 3.66 (q, br, 2 H), 3.40 (q, br, 2 H), 3.25 (m, 1 H), 3.05, (m, 6 H), 2.73 (m, 1 H), 1.42 (t, br, 3 H), 1.22 (t, br, 3 H) ^{13}C NMR (CDCl_3 , 100 MHz, 25 °C): δ 153.7, 149.5, 141.3, 139.5, 139.3, 135.1, 133.4, 133.0, 132.2, 131.1, 129.5, 129.4, 128.6, 42.2, 41.9, 35.3, 34.9, 34.6, 31.7, 14.5, 13.5.

Barrett, D.G.; Hopf, H. *Liebigs. Ann.* **1995**, 449-451.

O-[4-(5-iodo-[2.2]paracyclophanyl)] diethylcarbamate




In a 250 mL Schlenk tube, a solution of O-(4-[2.2]paracyclophanyl) diethylcarbamate (2.16 mmol, 698.9 mg) in 55 mL of anhydrous tetrahydrofuran (THF) was treated with tetramethylethyldiamine (TMEDA) (2.6 mmol, 0.39 mL) and cooled to -78 °C. The resulting mixture was treated with sec-butyllithium (1.4 M in cyclohexane, 2.92 mmol, drop wise) and stirred at -78 °C for 2 h. The reaction mixture became clear yellow. After 2 h, a solution of diiodoethane (6.48 mmol, 1.83 g) in anhydrous THF was added drop wise to the reaction mixture. The resulting mixture was then allowed to slowly warm to room temperature overnight. After 15 h, the solution had turned dark purple. The THF was removed in vacuo and the residue dissolved in 55 mL of Et_2O and

55 mL of aqueous 5% sodium thiosulfate. The organic layer was washed again with an additional 55 mL of aqueous 5% sodium thiosulfate. The aqueous phase was extracted with Et₂O (3 x 20 mL). The organic layers were combined, washed with 20 mL 1 M HCl, and dried over Na₂SO₄. The solvent was evaporated to afford an off-white crystalline solid (949.2 mg, 98%). ¹H NMR (CDCl₃, 400 MHz, 25 °C): δ 7.14 (d, J = 8.0 Hz, 1 H), 6.67 (d, J = 7.3 Hz, 1 H), 6.52 – 6.60 (m, 3 H), 6.45 (d, J = 7.8 Hz, 1 H), 3.77 – 3.85 (m, 1 H), 3.52 – 3.61 (m, 1 H), 3.35 – 3.47 (m, 3H), 2.97 – 3.21 (m, 6 H), 2.78 – 2.86 (m, 1 H), 1.50 (t, J = 7.1 Hz, 3 H), 1.23 (t, J = 7.1 Hz, 3 H). ¹³C NMR (CDCl₃, 100 MHz, 25 °C): δ 152.6, 149.1, 145.3, 139.1, 138.6, 134.4, 133.3, 132.9, 132.9, 130.6, 128.9, 128.6, 103.6, 42.4, 42.1, 39.2, 34.5, 33.0, 31.8, 14.7, 13.4.

Wack, H.; France, S.; Hafez, A.; Drury, W.; Weatherwax, A.; Lectka, T. *J. Org. Chem.* **2004**, *69*, 4531.

4-Hydroxy-5-iodo-[2.2]paracyclophane




In a 50 mL round bottom flask, O-[4-(5-iodo-[2.2]paracyclophanyl)] diethylcarbamate (930.8 mg, 2.07 mmol) and potassium hydroxide (2.90 g, 51.75 mmol) were suspended in 15 mL of ethylene glycol. Hydrazine (331.7 mg, 10.35 mmol) was added and the mixture was heated at reflux for 2 h. During the reflux period, the mixture became homogenous. The solution was cooled to room temperature, transferred to a separatory funnel, acidified to pH 1 with 1 M HCl, and diluted with deionized water. The

aqueous phase was extracted with Et₂O (4 x 40 mL). The organic layers were combined, dried over Na₂SO₄, and solvent was removed in vacuo to afford an off-white solid (550.2 mg, 78%). ¹H NMR (CDCl₃, 400 MHz, 25 °C): δ 7.04 (dd, J = 7.8, 1.5 Hz, 1 H), 6.78 (dd, J = 7.8, 1.5 Hz, 1 H), 6.47 – 6.57 (m, 3 H), 6.27 (d, J = 7.6 Hz, 1H), 5.12 (s, 1 H), 3.38 – 3.44 (m, 1 H), 3.25 – 3.33 (m, 1 H), 2.96 – 3.15 (m, 5 H), 2.69 – 2.76 (m, 1 H). ¹³C NMR (CDCl₃, 100 MHz, 25 °C): δ 152.3, 144.5, 139.7, 137.7, 134.9, 133.1, 133.0, 128.1, 127.3, 126.2, 125.6, 99.5, 39.3, 34.0, 32.9, 31.5.

Wack, H.; France, S.; Hafez, A.; Drury, W.; Weatherwax, A.; Lectka, T. *J. Org. Chem.* **2004**, *69*, 4531.

4-Methoxy-5-iodo-[2.2]paracyclophane




In a 100 mL glass tube sealed with a Teflon screw cap closure, potassium carbonate (992.3 mg, 7.18 mmol) and 4-hydroxy-5-iodo[2.2]paracyclophane (548.3 mg, 1.56 mmol) were heated to 70 °C in 15 mL of acetone for 30 minutes. Iodomethane (553.6 mg, 3.90 mmol) was added to the mixture, the tube was sealed, and the stirred solution was heated at 70 °C for 1 day. The mixture was transferred to a round bottom flask, the solvent was removed by rotary evaporation and the remaining solid was treated with 15 mL of deionized water and 15 mL of dichloromethane, and transferred to a separatory funnel. The aqueous layer was extracted with dichloromethane (3 x 30 mL).

The organic layers were combined, dried over Na₂SO₄, and the solvent was removed in vacuo to yield a nearly colorless oil. This somewhat insoluble material was dissolved in hot hexanes, loaded onto a silica gel column, and eluted with 10% EtOAc/hexanes) to afford an almost colorless product (416.7 mg, 73%) ¹H NMR (CDCl₃, 400 MHz, 25 °C): δ 7.09 (d, J = 7.9 Hz, 1 H), 6.70 (d, J = 7.9 Hz, 1 H), 6.53 (d, J = 7.7 Hz, 1 H), 6.52 (s, 2 H), 6.35 (d, J = 7.7 Hz, 1 H), 3.64 (s, 3 H), 3.38 – 3.43 (m, 1 H), 3.26 – 3.33 (m, 1 H), 3.08 – 3.19 (m, 2 H), 2.92 – 3.03 (m, 3 H), 2.74 – 2.81 (m, 1 H). ¹³C NMR (CDCl₃, 100 MHz, 25 °C): δ 157.7, 145.6, 139.4, 138.4, 135.2, 132.8, 132.7, 131.8, 129.4, 128.9, 128.7, 103.5, 60.9, 39.2, 34.5, 33.0, 31.2.

Wack, H.; France, S.; Hafez, A.; Drury, W.; Weatherwax, A.; Lectka, T. *J. Org. Chem.* **2004**, *69*, 4531.


4-Methoxy-7-iodo[2.2]paracyclophane



In a 100 mL round bottom flask, a solution of 4-methoxy[2.2]paracyclophane (0.8 mmol, 192.3 mg) in CH₂Cl₂ (25 mL) of CH₂Cl₂ was treated with a solution of N-iodosuccinimide (0.648 mmol, 145.2 mg) and trifluoroacetic acid (0.648 mmol, 75.3 mg) in 25 mL of dichloromethane. The resulting mixture was stirred for 5 minutes and the

dark purple color of iodine developed. The solution was transferred to a separatory funnel and washed (3 x 50 mL) with 2 M aqueous sodium bicarbonate solution followed by a single deionized water wash. The organic layer was separated, dried over Na₂SO₄, and the solvent was evaporated to give an off-white solid (295.0 mg, 99%). ¹H NMR (CDCl₃, 400 MHz, 25 °C): δ 7.13 (dd, J = 7.9, 1.8 Hz, 1 H), 6.75 (dd, J = 7.9, 1.8 Hz, 1 H), 6.71 (s, 1 H), 6.46 (dd, J = 7.9, 1.8, 1 H), 6.40 (dd, J = 7.8, 1.8 Hz, 1 H), 5.69 (s, 1 H), 3.68 (s, 3 H), 2.82-3.37 (m, 7 H), 2.43-2.53 (m, 1H). ¹³C NMR (CDCl₃, 100 MHz, 25 °C): δ 157.9, 144.7, 143.9, 139.9, 138.5, 132.9, 131.5, 129.9, 129.6, 128.9, 117.7, 91.9, 54.3, 39.3, 33.6, 33.2, 31.1.

4-Methoxy-7-bromo[2.2]paracyclophane




N-Bromosuccinimide (279.4 mg, 1.57 mmol) and trifluoroacetic acid (179.0 mg, 0.12 mL, 1.57 mmol) were dissolved in 15 mL of CH₂Cl₂ and added to a solution of 4-methoxy[2.2]paracyclophane (349.7 g, 1.47 mmol) in 30 mL CH₂Cl₂. The resulting mixture was covered from light and stirred for 30 minutes at room temperature. The solution was transferred to a separatory funnel and washed (3 x 50 mL) with 2 M aqueous sodium bicarbonate solution followed by a single deionized water wash. The organic

layer was separated, dried over Na₂SO₄, and the solvent was evaporated to give light brown solid (400.6 mg, 86%). ¹H NMR (CDCl₃, 400 MHz, 25 °C): δ 7.10 (dd, J = 7.8, 1.8 Hz, 1 H), 6.76 (dd, J = 7.9, 1.9 Hz, 1 H), 6.41 - 6.46 (m, 3 H), 5.69 (s, 1 H), 3.71 (s, 3 H), 3.34 - 3.45 (m, 2 H), 3.18 - 3.25 (m, 1 H), 2.98 - 3.10 (m, 3 H), 2.71 - 2.78 (m, 1 H), 2.46 - 2.54 (m, 1 H); ¹³C NMR (CDCl₃, 100 MHz, 25 °C) δ 157.15, 140.81, 139.95, 138.76, 138.65, 133.19, 133.16, 131.83, 130.00, 129.19, 118.54, 117.26, 54.69, 35.89, 33.82, 33.51, 31.29.

Rozenberg, V.; Zhuravsky, R.; Sergeeva, E. *Chirality* **2006**, *18*, 95-102.


[(2.2]Paracyclophan-4-yl)(2',5'-dimethylphenyl)iodonium hexafluorophosphate, 2-1



In a 50 mL Schlenk tube under nitrogen, a stirred solution of 4-bromocyclophane (1 mmol, 282 mg) in 10 mL of anhydrous diethyl ether was cooled to -78 °C. A solution of *t*-BuLi (1.7 M in pentane, 2.3 equiv.) was added dropwise and the resulting mixture was stirred at -78 °C for 20 minutes and then warmed to 0 °C and allowed to stir for an additional 20 min. The reaction mixture was cooled again to -78 °C before a solution of zinc chloride (200 mg, 1.5 mmol) in ether (10 mL) was added dropwise by cannula. After the addition, the reaction mixture was allowed to warm to room temperature over the

course of one hour before the solvents were removed in vacuo. The remaining solid was dissolved in anhydrous CH₃CN and the solution was cooled to -40 °C and added dropwise to precooled (-40 °C) suspension of bis(acetyloxy)-(2,5-dimethylphenyl)-λ₃-iodane (350 mg, 1 mmol) in 10 mL of acetonitrile. The mixture was allowed to warm to room temperature over 30 minutes before the solvent was removed in vacuo. The resulting solid was washed with hexanes and then dissolved in aqueous acetonitrile. Addition of an aqueous NaPF₆ solution precipitated the product, which was extracted from the aqueous mixture with CH₂Cl₂. The organic layer was evaporated, dissolved in a minimal amount of CH₂Cl₂, precipitated with hexanes, filtered and dried in vacuo to yield **1** (105 mg, 18 % yield). ¹H NMR (CD₃CN, 400 MHz, 25 °C): δ 7.93 (s, 1H), 7.41 (s, 2H), 7.29 (d, J = 1.3 Hz, 1H), 6.84 (dd, J₁ = 7.8 Hz, J₂ = 1.3 Hz, 1H), 6.78 (d, J = 7.8 Hz, 1H), 6.66 (s, 2H), 6.53 (d, J = 7.9 Hz, 1H), 6.51 (d, J = 7.9 Hz, 1H), 3.04-3.41 (m, 8H), 2.50 (s, 3H), 2.33 (s, 3H); ¹³C NMR (CD₃CN, 100 MHz, 25 °C) δ 146.5, 143.6, 141.9, 141.1, 140.2, 139.9, 139.5, 138.2, 137.7, 135.6, 134.7, 134.5, 134.1, 133.9, 133.1, 132.5, 120.6, 118.8, 100.8, 38.9, 35.8, 35.5, 35.4, 25.3, 20.6; HRMS: (HRFAB) calcd. for C₂₄H₂₄I [M]⁺ 439.0923, found 439.0907.


[(2.2]Paracyclophan-4-yl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 2-3



In a 50 mL Schlenk tube under nitrogen, a stirred solution of bromocyclophane (1 mmol, 282 mg) in 10 mL of anhydrous diethyl ether was cooled to $-78\text{ }^{\circ}\text{C}$. A solution of *t*-BuLi (1.7 M in pentane, 2.3 equiv.) was added dropwise and the resulting mixture was stirred at $-78\text{ }^{\circ}\text{C}$ for 20 minutes and then warmed to $0\text{ }^{\circ}\text{C}$ and allowed to stir for an additional 20 min. The reaction mixture was cooled again to $-78\text{ }^{\circ}\text{C}$ before a solution of zinc chloride (200 mg, 1.5 mmol) in ether (10 mL) was added dropwise by cannula. After the addition, the reaction mixture was allowed to warm to room temperature over the course of one hour before the solvents were removed in vacuo. The remaining solid was dissolved in anhydrous CH_3CN and the solution was cooled to $-40\text{ }^{\circ}\text{C}$ and added dropwise to precooled ($-40\text{ }^{\circ}\text{C}$) suspension of bis(acetyloxy)-(4-methoxyphenyl)- λ_3 -iodane (352 mg, 1 mmol) in 10 mL of acetonitrile. The mixture was allowed to warm to room temperature over 30 minutes before the solvent was removed in vacuo. The resulting solid was washed with hexanes and then dissolved in aqueous acetonitrile. Addition of an aqueous NaPF_6 solution precipitated the product, which was extracted from the aqueous mixture with CH_2Cl_2 . The organic layer was evaporated, dissolved in a minimal amount of CH_2Cl_2 , precipitated with hexanes, filtered and dried in vacuo to yield **2** (225 mg, 38.4 % yield). ^1H NMR (CD_3CN , 400 MHz, $25\text{ }^{\circ}\text{C}$): δ 8.00 (d, $J = 9.1\text{ Hz}$, 2H), 7.27 (s, 1H), 7.08 (d, $J = 9.1\text{ Hz}$, 2H), 6.83 (d, $J = 7.7\text{ Hz}$, 1H), 6.76 (d, $J = 7.7\text{ Hz}$,


1H), 6.65 (s (broad), 2H), 6.38 (d, J = 7.9 Hz, 1H), 6.31 (d, J = 7.9 Hz, 1H), 3.84 (s, 3H), 3.04-3.35 (m, 8H); ^{13}C NMR (CD_3CN , 100 MHz, 25 °C) δ 164.1, 143.2, 140.9, 139.8, 139.4, 139.2, 138.8, 137.6, 134.3, 134.2, 133.7, 132.4, 120.9, 119.4, 100.8, 56.7, 38.4, 35.6, 35.4, 35.3; HRMS: (HRFAB) calcd. for $\text{C}_{23}\text{H}_{22}\text{OI}$ $[\text{M}]^+$ 441.07098, found 441.0712.

**(7-Methoxy[2.2]paracyclophanyl)(4'-methoxyphenyl)iodonium
hexafluorophosphate, 2-5**



In a 100 mL Schlenk tube, 4-methoxy-7-bromo[2.2]paracyclophane (1.26 mmol, 400.6 mg) was dissolved in 25 mL of distilled ether and cooled to -78 °C. To the cooled solution, 1.7M t-butyl lithium (3.16 mmol, 1.85 mL) was added dropwise and the stirred solution was held at -78 °C for 1 hour. A solution of anhydrous zinc chloride (1.51 mmol, 206.1 mg) in 10 mL of diethyl ether was added dropwise to the cooled solution. The mixture was allowed to warm to room temperature, and the solvent was removed under reduced pressure. The residual solid (organozinc chloride reagent and lithium salts) was taken up in anhydrous acetonitrile and cooled to -40 °C before a solution of 4-methoxyphenyl iodonium diacetate (1.89 mmol, 665.5 mg) in acetonitrile (10 mL) was added in a dropwise fashion. After 1 hour at -40 °C, the mixture was warmed to room temperature and the solvent was removed under reduced pressure. Deionized water and


sodium hexafluorophosphate (410 mg) were added, followed by 50 mL of dichloromethane. The mixture was transferred to a separatory funnel and the organic phase was separated. The solvent was removed by rotary evaporation and the remaining solid was dissolved in 5 mL of dichloromethane and dripped into 150 mL hexanes. The precipitate was aged for one hour, collected by gravity filtration, and dried in vacuo to yield a colorless salt (55.6 %, 431.7 mg).



^1H NMR (CD_3CN , 400 MHz, 25 °C): δ 8.01 (d, J = 9.2 Hz, 2H, H2', H6'), 7.25 (s, 1H, H8), 7.07 (d, J = 9.2 Hz, 2H, H3', H5'), 6.81 (dd, J = 7.8, 1.8 Hz, 1H, H15), 6.62 (dd, J = 7.9, 1.9 Hz, 1H, H16), 6.29 (dd, J = 7.9, 1.6 Hz, 1H, H13), 6.12 (dd, J = 8.0, 2.0 Hz, 1H, H12), 6.02 (s, 1H, H5), 3.83 (s, 3H, Me_a), 3.74 (s, 3H, Me_b), 3.31 (ddd, J = 11.6, 9.8, 1.7 Hz, 1H, H2a), 3.26 (dd, J = 8.4, 5.7 Hz, 1H, H9b), 3.23 (dd, J = 13.9, 4.3 Hz, 1H, H9a), 3.18 (dd, J = 12.9, 4.1 Hz, 1H, H10b), 3.15 (dd, J = 8.3, 3.0 Hz, 1H, H10a), 3.05 (ddd, J = 12.8, 9.9, 6.4 Hz, 1H, H1a), 3.02 (ddd, J = 12.8, 9.9, 6.4 Hz, 1H, H1b), 2.68 (ddd, J = 13.1, 10.5, 6.4 Hz, 1H, H2b). ^{13}C NMR (CD_3CN , 400 MHz, 25 °C): δ 163.3 (C4), 161.6

(C4'), 146.4 (C6), 140.5 (C8), 139.9 (C11), 137.9 (C14), 137.4 (C2', C6'), 133.2 (C13), 132.4 (C3), 131.4 (C12), 131.3 (C16), 128.8 (C15), 119.8 (C5), 118.2 (C3', C5'), 107.4 (C7), 101.1 (C1'), 55.8 (Me_a), 54.9 (Me_b), 37.2 (C9), 34.5 (C10), 32.9 (C1), 30.7 (C2).
¹⁹F NMR (CD₃CN, 400 MHz, 25 °C): δ -72.7 (d, J = 706.7 Hz, 6F). HRMS: (HRFAB) calcd. for C₂₄H₂₄IO₂ [M]⁺ 471.08210 (100%), 472.08454 (26%); found 471.08221 (100%), 472.08561 (23%).

**(5-(4-Methoxy[2.2]paracyclophanyl))(4'-methoxyphenyl)iodonium
 hexafluorophosphate, 3-1**



In a 100 mL Schlenk tube, 4-methoxy-5-iodo-[2.2]paracyclophane (1.14 mmol, 416.7 mg) was dissolved in 25 mL of distilled ether and cooled to -78 °C. To this stirred solution, 1.7 M t-butyl lithium (2.85 mmol, 1.68 mL) was added dropwise and the solution was held at -78 °C for 1 hour. A solution of anhydrous zinc chloride (1.37 mmol, 190.0 mg) in 10 mL of diethyl ether was added dropwise to the cold solution over the course of 1 h. The mixture was allowed to warm to room temperature, and the solvent was removed under reduced pressure. The residual solid (comprising organozinc chloride reagent and lithium salts) was taken up in anhydrous acetonitrile and cooled to -40 °C before a solution of 4-methoxyphenyl iodonium diacetate (1.89 mmol, 665.5 mg) in

acetonitrile (10 mL) was added in a dropwise fashion. After 1 hour at $-40\text{ }^{\circ}\text{C}$, the mixture was allowed to warm to room temperature and the solvent was removed under reduced pressure. Deionized water and sodium hexafluorophosphate (470 mg) were added, followed by 50 mL of dichloromethane. The mixture was transferred to a separatory funnel and the organic phase was separated. The solvent was removed by rotary evaporation and the remaining solid was dissolved in 5 mL of dichloromethane and dripped into 150 mL hexanes. The precipitate was aged for one hour, collected by gravity filtration, and dried in vacuo to yield a colorless salt (13.0 %, 91.0 mg). ^1H NMR (CD_3CN , 400 MHz, $25\text{ }^{\circ}\text{C}$): δ 7.99 (d, 9.3 Hz, 2H), 7.07 (d, 9.2 Hz, 2H), 6.84 (d, 7.8 Hz, 1H), 6.59- 6.69 (m, 4H), 6.11 (d, 7.9 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.32 – 3.38 (m, 1H), 3.06 – 3.26 (m, 6H), 2.93 – 3.00 (m, 1H). ^{13}C NMR (CD_3CN , 400 MHz, $25\text{ }^{\circ}\text{C}$): δ 163.4, 156.9, 144.9, 142.3, 140.0, 138.3, 138.2, 133.7, 133.3, 133.2, 131.8, 130.4, 129.2, 118.3, 99.3, 62.5, 55.8, 36.9, 33.8, 33.7, 31.9. ^{19}F NMR (CD_3CN , 400 MHz, $25\text{ }^{\circ}\text{C}$): δ -72.8 (d, $J = 706.9\text{ Hz}$, 6F). HRMS: (HRFAB) calcd. for $\text{C}_{24}\text{H}_{24}\text{IO}_2\text{ [M]}^+$ 471.0821, found 471.0806.

Appendix A

Common abbreviations used in this thesis

PET	Positron Emission Tomography
TMAOH	Tetramethylammonium hydroxide
TMAF	Tetramethylammonium fluoride
[¹⁸ F]FDG	2-[¹⁸ F]Fluoro-2-deoxy-D-glucose
CsF	Cesium fluoride
K2.2.2KF	Kryptofix 2.2.2. KF
CH ₃ CN	Acetonitrile
C ₆ H ₆	Benzene
TMAPF ₆	Tetramethylammonium hexafluorophosphate
F-MTEB	3-Fluoro-5-[(2-methyl-1,3-thiazol-4-yl)ethynyl]benzotrile
F-DOPA	6-fluorodihydroxyphenylalanine
TMEDA	Tetramethylethyl diamine
t-BuLi	t-Butyl Lithium
n-BuLi	n-Butyl Lithium

Appendix B
NMR Spectra

Contents of Appendix B


NMR Spectra

1. ^1H of 4-Bromo[2.2]paracyclophane in CDCl_3
2. ^{13}C of 4-Bromo[2.2]paracyclophane in CDCl_3
3. ^1H of 4-Hydroxy[2.2]paracyclophane in CDCl_3
4. ^{13}C of 4-Hydroxy[2.2]paracyclophane in CDCl_3
5. ^1H of 4-Methoxy[2.2]paracyclophane in CDCl_3
6. ^{13}C of 4-Methoxy[2.2]paracyclophane in CDCl_3
7. ^1H of 4-Methoxy-7-iodo[2.2]paracyclophane in CDCl_3
8. ^{13}C of 4-Methoxy-7-iodo[2.2]paracyclophane in CDCl_3
9. ^1H of 4-Methoxy-7-bromo[2.2]paracyclophane in CDCl_3
10. ^{13}C of 4-Methoxy-7-bromo[2.2]paracyclophane in CDCl_3
11. ^1H , ^{13}C HSQC of 4-Methoxy-7-bromo[2.2]paracyclophane in CDCl_3
12. ^1H , ^{13}C HSQC of 4-Methoxy-7-bromo[2.2]paracyclophane (aliphatic) in CDCl_3
13. ^1H , ^{13}C HSQC of 4-Methoxy-7-bromo[2.2]paracyclophane (aromatic) in CDCl_3
14. ^1H and ^{13}C NMR spectra of ([2.2]Paracyclophan-4-yl)(2',5'-dimethylphenyl)iodonium hexafluorophosphate, 2-1 in CD_3CN

15. ^1H and ^{13}C NMR spectra of ([2.2]Paracyclophan-4-yl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 2-3 in CD_3CN
16. ^1H , ^{13}C HMQC spectrum of ([2.2]Paracyclophan-4-yl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 2-3 in CD_3CN
17. ^1H and ^{13}C NMR spectra of (7-Methoxy[2.2]paracyclophanyl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 2-5 in CD_3CN
18. ^1H , ^{13}C HSQC spectrum of (7-Methoxy[2.2]paracyclophanyl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 2-5 in CD_3CN
19. ^1H , ^{13}C HSQC spectrum of (7-Methoxy[2.2]paracyclophanyl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 2-5 in CD_3CN (aliphatic)
20. ^1H , ^{13}C HSQC spectrum of (7-Methoxy[2.2]paracyclophanyl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 2-5 in CD_3CN (aromatic)
21. ^1H , ^{13}C HSQC-HMBC spectrum of (7-Methoxy[2.2]paracyclophanyl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 2-5 in CD_3CN
22. ^1H - ^1H COSY spectrum of (7-Methoxy[2.2]paracyclophanyl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 2-5 in CD_3CN
23. ^1H - ^1H NOESY spectrum of (7-Methoxy[2.2]paracyclophanyl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 2-5 in CD_3CN (full)
24. ^1H - ^1H NOESY spectrum of (7-Methoxy[2.2]paracyclophanyl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 2-5 in CD_3CN (aliphatic-aliphatic)

25. ^1H - ^1H NOESY spectrum of (7-Methoxy[2.2]paracyclophanyl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 2-5 in CD_3CN (aliphatic-aromatic)
26. ^1H - ^1H NOESY spectrum of (7-Methoxy[2.2]paracyclophanyl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 2-5 in CD_3CN (aromatic-aromatic)
27. ^1H of O-(4-[2.2]paracyclophanyl) Diethylcarbamate in CDCl_3
28. ^{13}C of O-(4-[2.2]paracyclophanyl) Diethylcarbamate in CDCl_3
29. ^1H of O-[4-(5-Iodo-[2.2]paracyclophanyl)] Diethylcarbamate in CDCl_3
30. ^{13}C of O-[4-(5-Iodo-[2.2]paracyclophanyl)] Diethylcarbamate in CDCl_3
31. ^1H of 4-Hydroxy-5-iodo-[2.2]paracyclophane in CDCl_3
32. ^{13}C of 4-Hydroxy-5-iodo-[2.2]paracyclophane in CDCl_3
33. ^1H of 4-Methoxy-5-iodo-[2.2]paracyclophane in CDCl_3
34. ^{13}C of 4-Methoxy-5-iodo-[2.2]paracyclophane in CDCl_3
35. ^1H of (4-Methoxy[2.2]paracyclophanyl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 3-1 in CD_3CN
36. ^{13}C of (4-Methoxy[2.2]paracyclophanyl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 3-1 in CD_3CN
37. ^1H - ^1H COSY spectrum of (4-Methoxy[2.2]paracyclophanyl)(4'-methoxyphenyl)iodonium hexafluorophosphate, 3-1 in CD_3CN


1D Proton NMR



NAME jg-bromocyclopentane-092609

EXPNO 1
PROCNO 1
Date_ 20090926
Time_ 10.14
INSTRUM spect
PROBHD 5 mm QNP 1H/13
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 8278.146 Hz
FIDRES 0.126314 Hz
AQ 3.958424 sec
RG 60.402
DQ 6.402 usec
DE 6.402 usec
TE 283.8 K
D1 1.00000000 sec
TD0 1


----- CHANNEL f1 -----
NUC1 1H
P1 12.00 usec
PL1 -2.35 dB
SFO1 400.1324710 MHz
SI 32768
SF 400.1300000 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00






Current Data Parameters
NAME JG-bromocyclophane-13C-110509-1
PROCNO 1

F2 - Acquisition Parameters
Time 200.13.37
INSTRUM spect
PROBHD 5 mm QNP 1H/13
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
DS 814
SWH 23980.814 Hz
FIDRES 1.3668756 sec
AQ 812.7
RG 20.850 usec
DM 20.850 usec
TE 295.3 K
D1 2.0000000 sec
D2 0.0300000 sec
D3 0.0300000 sec
D4 0.0300000 sec
D5 0.0300000 sec
D6 0.0300000 sec
D7 0.0300000 sec
D8 0.0300000 sec
D9 0.0300000 sec
D10 0.0300000 sec
D11 0.0300000 sec
D12 0.0300000 sec
D13 0.0300000 sec
D14 0.0300000 sec
D15 0.0300000 sec
D16 0.0300000 sec
D17 0.0300000 sec
D18 0.0300000 sec
D19 0.0300000 sec
D20 0.0300000 sec
===== CHANNEL f1 =====
NUC1 13C
P1 10.00 usec
PL1 0.00 dB
SFO1 100.6228298 MHz
===== CHANNEL f2 =====
wait 1
NUC2 1H
P2 70.00 usec
PL2 -3.35 dB
PL12 11.97 dB
PL13 11.97 dB
SFO2 400.1316005 MHz
F2 - Processing parameters
SI 32768
SF 100.6127650 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40





35.85
37.48
34.82
33.47

141.61
139.33
139.11
137.25
135.05
133.31
133.02
132.91
132.25
131.46
128.69
126.97



13C

1D Proton NMR






3,5-dihydroxy-1,4-naphthoquinone-1,3-dic-110909


NAME 3,5-dihydroxy-1,4-naphthoquinone-1,3-dic-110909
 PROCNO 1
 DATE_ 20081102
 TIME_ 11:18
 INSTRUM spect
 PROBRD 5 mm QNP 1H/13
 EDUROC DEJ36
 SOLVENT CDCl3
 DS 34.4
 SWH 23980.814 Hz
 FREQS 0.36092 MHz
 RG 1.36092 sec
 AQ 812.7 sec
 DM 20.950 usec
 DE 0.5 usec
 TE 300.2 K
 D1 2.0000000 sec
 D11 0.0300000 sec
 TD0

===== CHANNEL F1 =====
 PUL1 10.00 usec
 PL1 0.50 dB
 SFO1 100.622928 MHz
 ===== CHANNEL F2 =====
 CPDPRG2 waltz16
 FREQ2 70.00 usec
 PL2 -2.15 dB
 PL12 11.7 dB
 SFO2 400.131405 MHz
 SI 3278
 SF 100.612768 MHz
 WDM 1.00 Hz
 SS 1.40 Hz
 EC




35.31
34.82
33.84
31.10

153.67
142.01
139.63
138.84
135.46
133.04
132.77
131.86
127.95
125.44
125.04
122.57



13C


1D Proton NMR



NAME JG-PCOMs-char-1H

EXPNO 1
 PROCNO 1
 Date_ 20100122
 Time_ 10.48
 INSTRUM spect
 PROBRD 5 mm QNP 1H/13
 PULPROG zgpg30
 TD 65536
 ID 65536
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 9278.146 Hz
 FIDRES 0.126314 Hz
 AQ 3.9584243 sec
 RG 64
 LW 60.400 usec
 LE 6.50 usec
 TE 293.7 K
 D1 1.0000000 sec
 TDO 1

----- CHANNEL f1 -----
 NUC1 1H
 P1 12.00 usec
 PL1 -3.35 dB
 SF01 400.1324710 MHz
 S1 32768
 SF 400.1300555 MHz
 WIM EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



13C




JG-PCOMs-char-13C

NAME EXPNO PROCNO 1
 DATE_ 20100122
 TIME_ 12.08
 INSTRUM spect
 PROBRD 5 mm QNP 1H/13
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 512
 DS 4
 SWH 23080.814 Hz
 FIDRES 0.365318 Hz
 AQ 1.3664756 sec
 RG 812.7
 DW 20.850 usec
 DE 6.50 usec
 TE 294.1 K
 D1 2.00000000 sec
 D11 0.03000000 sec
 TDO 1


----- CHANNEL f1 -----
 NUC1 13C
 P1 10.00 usec
 PL1 0.50 dB
 SF01 100.6228298 MHz

----- CHANNEL f2 -----
 CPDPRG2 waltz16
 NUC2 1H
 P2 70.00 usec
 PL2 -3.35 dB
 PL12 11.97 dB
 PL13 11.97 dB
 SF02 400.1316005 MHz
 SI 32768
 SF 100.6127554 MHz
 KIM EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40



157.60
 142.10
 140.25
 138.83
 135.00
 133.65
 133.12
 131.51
 28.36
 27.53
 24.44
 16.74

54.25
 35.50
 35.42
 34.09
 31.67




200 180 160 140 120 100 80 60 40 20 0 ppm



Current Data Parameters
 NAME: KXPR0
 JC-P-methoxyiodocyclophane-13C-10069
 PROCNO: 1


F2 - Acquisition Parameters
 Date_ 20081103
 Time_ 14:00
 INSTRUM spect
 INTRPROG zgpg30
 PULPROG zgpg30
 ID: 55236
 ACQ: 55236
 NS: 252
 DS: 4
 SWH: 23960.814 MHz
 FIDRES: 0.265318 MHz
 AQ: 1.3668577 sec
 RG: 812.7 MC
 DW: 20.850 usec
 DE: 1.00 usec
 TE: 293.0 K
 D1: 0.0500000 sec
 D11: 0.0500000 sec
 D12: 0.0500000 sec
 D13: 0.0500000 sec
 D14: 0.0500000 sec
 D15: 0.0500000 sec
 D16: 0.0500000 sec
 D17: 0.0500000 sec
 D18: 0.0500000 sec
 D19: 0.0500000 sec
 D20: 0.0500000 sec
 CHANNEL F1
 NUC1 13C
 P1 10.00 usec
 PL1 0.00 dB
 SFO1 100.628258 MHz
 =====
 CHANNEL F2
 NUC2 1H
 P2 9.00 usec
 PL2 0.00 dB
 SFO2 400.146005 MHz
 =====
 Processing parameters
 SI 32768
 SF 100.612769 MHz
 DF 300.000 MHz
 AS 0
 SSB 0
 CB 1.00 Hz
 GB 0
 PC 1.40

157.97
 144.69
 143.91
 139.86
 138.46
 132.90
 131.54
 129.98
 129.59
 128.87
 117.66
 91.85
 54.28
 39.30
 33.61
 33.17
 31.11



13C

ppm



1D Proton NMR



Current Data Parameters
 NAME 3G-PCMO6-conc-011310-1H
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters


File_ 201013
 Date_ 10.02
 Time_ 16.02
 INSTRUM spect
 PULPROG zgpg30
 PROCNO 1
 TD 65536
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 9279.146 Hz
 FIDRES 0.126314 Hz
 AQ 3.2594243 sec
 RG 191
 SF 400.1324710 MHz
 DF 60.400 usec
 DE 6.50 usec
 TE 294.1 K
 D1 1.00000000 sec
 TD0 1


===== CHANNEL f1 =====

NUC1 13C
 P1 12.00 usec
 PL1 0.00 dB
 SFO1 400.1324710 MHz

F2 - Processing Parameters

SI 32768
 SF 400.130055 MHz
 WDM 0
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00






EZ-HSQC



NAME J3-PCR06a-coc-13C
 PROCNO 1
 Date_ 20100815
 Time 11:02
 INSTRUM spect
 PROCES 5 nm QNP 1H/13
 TO F2F0G
 TD 65536
 SFOV 102.4
 SOLVENT CDCl3
 NS 4
 DS 16
 SWH 3294.739 Hz
 FIDRES 0.1207028 Hz
 AQ 0.123904
 RG 327.5
 DN 147.208 umax
 DE 6.58 umax
 TE 294.2 K
 SFO2 145.008158 MHz
 C13 0.000000000
 S1 1.500000000 MHz
 S4 0.8012414 MHz
 S11 0.820000000 MHz
 S13 0.800000000 MHz
 S15 0.800000000 MHz
 SFOF05 0.800000000 MHz


CHANNEL F1	CHANNEL F2
NUC1 13C	NUC2 1H
F1 125.760 MHz	F2 500.1315095 MHz
F2a 205.108 MHz	
F11 -2.35 dB	
SFO1 400.1315095 MHz	
CH2F02 0 Hz	
SFO2 100.6202727 MHz	
CH2F02 0 Hz	
F3 18.00 MHz	
F4 28.00 MHz	
PCPD2 100.00 MHz	
F12 0.58 dB	
F13 0.58 dB	
SFO2 100.6202727 MHz	
GRD INT CHANNEL	
GF0M1 100.6202727 MHz	
GF0M2 100.6202727 MHz	
GF12 100.6202727 MHz	
GF13 100.6202727 MHz	
GF02 100.6202727 MHz	
GF03 100.6202727 MHz	
GF04 100.6202727 MHz	
GF05 100.6202727 MHz	
GF06 100.6202727 MHz	
GF07 100.6202727 MHz	
GF08 100.6202727 MHz	
GF09 100.6202727 MHz	
GF10 100.6202727 MHz	
GF11 100.6202727 MHz	
GF14 100.6202727 MHz	
GF15 100.6202727 MHz	
GF16 100.6202727 MHz	
GF17 100.6202727 MHz	
GF18 100.6202727 MHz	
GF19 100.6202727 MHz	
GF20 100.6202727 MHz	
GF21 100.6202727 MHz	
GF22 100.6202727 MHz	
GF23 100.6202727 MHz	
GF24 100.6202727 MHz	
GF25 100.6202727 MHz	
GF26 100.6202727 MHz	
GF27 100.6202727 MHz	
GF28 100.6202727 MHz	
GF29 100.6202727 MHz	
GF30 100.6202727 MHz	
GF31 100.6202727 MHz	
GF32 100.6202727 MHz	
GF33 100.6202727 MHz	
GF34 100.6202727 MHz	
GF35 100.6202727 MHz	
GF36 100.6202727 MHz	
GF37 100.6202727 MHz	
GF38 100.6202727 MHz	
GF39 100.6202727 MHz	
GF40 100.6202727 MHz	
GF41 100.6202727 MHz	
GF42 100.6202727 MHz	
GF43 100.6202727 MHz	
GF44 100.6202727 MHz	
GF45 100.6202727 MHz	
GF46 100.6202727 MHz	
GF47 100.6202727 MHz	
GF48 100.6202727 MHz	
GF49 100.6202727 MHz	
GF50 100.6202727 MHz	
GF51 100.6202727 MHz	
GF52 100.6202727 MHz	
GF53 100.6202727 MHz	
GF54 100.6202727 MHz	
GF55 100.6202727 MHz	
GF56 100.6202727 MHz	
GF57 100.6202727 MHz	
GF58 100.6202727 MHz	
GF59 100.6202727 MHz	
GF60 100.6202727 MHz	
GF61 100.6202727 MHz	
GF62 100.6202727 MHz	
GF63 100.6202727 MHz	
GF64 100.6202727 MHz	
GF65 100.6202727 MHz	
GF66 100.6202727 MHz	
GF67 100.6202727 MHz	
GF68 100.6202727 MHz	
GF69 100.6202727 MHz	
GF70 100.6202727 MHz	
GF71 100.6202727 MHz	
GF72 100.6202727 MHz	
GF73 100.6202727 MHz	
GF74 100.6202727 MHz	
GF75 100.6202727 MHz	
GF76 100.6202727 MHz	
GF77 100.6202727 MHz	
GF78 100.6202727 MHz	
GF79 100.6202727 MHz	
GF80 100.6202727 MHz	
GF81 100.6202727 MHz	
GF82 100.6202727 MHz	
GF83 100.6202727 MHz	
GF84 100.6202727 MHz	
GF85 100.6202727 MHz	
GF86 100.6202727 MHz	
GF87 100.6202727 MHz	
GF88 100.6202727 MHz	
GF89 100.6202727 MHz	
GF90 100.6202727 MHz	
GF91 100.6202727 MHz	
GF92 100.6202727 MHz	
GF93 100.6202727 MHz	
GF94 100.6202727 MHz	
GF95 100.6202727 MHz	
GF96 100.6202727 MHz	
GF97 100.6202727 MHz	
GF98 100.6202727 MHz	
GF99 100.6202727 MHz	
GF100 100.6202727 MHz	





NAME
 WVSQ
 PROCNO 1
 Date_ 20100811S
 Time 11.02
 INSTRUM spect
 F2PROG 5 nm QNP 1H/13
 TD 65536
 TO 1024
 SOLVENT CDCl3
 NS 4
 DS 4
 SS 16
 AQ 3.2911238 Hz
 FIDRES 0.12637828 Hz
 AS 102390.4
 SN 147.208 usec
 SE 6.58 usec
 CK 29.12 E
 CHFT2 145.0028452 Hz
 SFO1 0.8003208 usec
 SFO2 1.50008008 usec
 SFO3 0.80172414 usec
 SFO4 0.8208008 usec
 SFO5 0.8003408 usec
 SFO6 0.8003208 usec
 SFO7NS 0.8003208 usec

ppm



ppm

E2-HSQC

30

35

40

45

50

55

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4

3.3

3.2

3.1

3.0

2.9

2.8

2.7

2.6

2.5

ppm

4.0

3.9

3.8

3.7

3.6

3.5

3.4


3.3

3.2


3.1


3.0


^1H NMR (CD_3CN , 400 MHz, 25 °C)





^{13}C NMR (CD_3CN , 100 MHz, 25 °C)












HSQC (CD₃CN, 25 °C, ¹H, 400 MHz, ¹³C, 100 MHz)-full







HSQC (CD₃CN, 25 °C, ¹H, 400 MHz, ¹³C, 100 MHz)-aromatic





HSQC(blue)-HMBC(black) (CD₃CN, 25 °C, ¹H, 400 MHz, ¹³C, 100 MHz)-full




COSY (CD₃CN, 25 °C, ¹H, 400 MHz, ¹³C, 100 MHz)-full




NOESY (CD₃CN, 25 °C, ¹H, 500 MHz, ¹³C, 100 MHz)-full





NOESY (CD₃CN, 25 °C, ¹H, 500 MHz, ¹³C, 100 MHz)-aliphatic/aliphatic





NOESY (CD₃CN, 25 °C, ¹H, 500 MHz, ¹³C, 100 MHz)-aromatic/aromatic





1D Proton NMR



NAME 3D-cyclopharylacarbamate-040710

EXPNO 1
 PROCNO 1
 Date_ 20100407
 Time 18.04
 INSTRUM 1H/13
 PROBE 5 mm QNP 1H/13
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 16
 DS 4
 SWH 8278.146 Hz
 FIDRES 0.126314 Hz
 AQ 3.9584243 sec
 RG 181
 DM 60.400 usec
 DE 6.50 usec
 DI 28800 K
 DQ 1.00000000 sec
 TD0 1


===== CHANNEL F1 =====
 NUC1 1H
 P1 10.25 usec
 PL1 0.00 dB
 SFO1 400.132435 MHz
 SF 400.1300054 MHz
 WDM 0
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00




BRUKER
 30-Jcp1cpahay1-conchadata-13c-040010


```

NAME          30-Jcp1cpahay1-conchadata-13c-040010
EXPNO         20100401
PROCNO        1
F1            11.31
F2            11.31
F3            11.31
PROBHD        5 mm QNP 1H/13
PULPROG       zgpg30
TD            65536
AQ            1.0214
RG            1024
SOLVENT       CDCl3
D1            2.00000000 sec
D11           0.03000000 sec
DELTA         23960.814 Hz
NUC1          13C
NUC2          1H
NUC3          1H
NUC4          1H
NUC5          1H
NUC6          1H
NUC7          1H
NUC8          1H
NUC9          1H
NUC10         1H
NUC11         1H
NUC12         1H
NUC13         1H
NUC14         1H
NUC15         1H
NUC16         1H
NUC17         1H
NUC18         1H
NUC19         1H
NUC20         1H
NUC21         1H
NUC22         1H
NUC23         1H
NUC24         1H
NUC25         1H
NUC26         1H
NUC27         1H
NUC28         1H
NUC29         1H
NUC30         1H
NUC31         1H
NUC32         1H
NUC33         1H
NUC34         1H
NUC35         1H
NUC36         1H
NUC37         1H
NUC38         1H
NUC39         1H
NUC40         1H
NUC41         1H
NUC42         1H
NUC43         1H
NUC44         1H
NUC45         1H
NUC46         1H
NUC47         1H
NUC48         1H
NUC49         1H
NUC50         1H
NUC51         1H
NUC52         1H
NUC53         1H
NUC54         1H
NUC55         1H
NUC56         1H
NUC57         1H
NUC58         1H
NUC59         1H
NUC60         1H
NUC61         1H
NUC62         1H
NUC63         1H
NUC64         1H
NUC65         1H
NUC66         1H
NUC67         1H
NUC68         1H
NUC69         1H
NUC70         1H
NUC71         1H
NUC72         1H
NUC73         1H
NUC74         1H
NUC75         1H
NUC76         1H
NUC77         1H
NUC78         1H
NUC79         1H
NUC80         1H
NUC81         1H
NUC82         1H
NUC83         1H
NUC84         1H
NUC85         1H
NUC86         1H
NUC87         1H
NUC88         1H
NUC89         1H
NUC90         1H
NUC91         1H
NUC92         1H
NUC93         1H
NUC94         1H
NUC95         1H
NUC96         1H
NUC97         1H
NUC98         1H
NUC99         1H
NUC100        1H
  
```



13C






Current Data Parameters
 NAME JC-o-iodoacetamide-041410-1H
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters

Date_ 20100414
 Time 14.56
 TIME 17.00
 PROBRD 5 mm QNP 1H/13
 PULPROG zgpg30
 ID 65836
 SOLVENT CDCl3
 NS 2
 DS 2
 SFR 8278.146 Hz
 AQ 0.358044 Hz
 FIDRES 3.358044 Hz
 PC 1.81
 LW 60.400 usec
 DE 3.50 usec
 DI 1.0000000 sec

===== CHANNEL f1 =====
 NUCL1 1H
 P1 10.25 usec
 PL1 -3.35 dB
 SFO1 400.1324710 MHz

F2 - Processing Parameters
 SI 32768
 SF 400.1300050 MHz
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00







Current Data Parameters
 NAME JG-o-iodocarbamate-13C
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160416
 Time 15:01
 INSTRUM spect
 PROSHD 5 ms COMP 16713
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 1024
 DS 4
 SWH 23960.814 Hz
 FIDRES 0.365318 Hz
 AQ 1.3664706 sec
 RG 1870
 DW 20.650 usec
 DE 298.0 K usec
 TE 298.0 K usec
 D1 2.00000000 sec
 D11 0.03000000 sec
 TD0 1


===== CHANNEL f1 =====
 NUC1 13C
 P1 10.00 usec
 PL1 0.50 dB
 SF01 100.6228298 MHz
 ===== CHANNEL f2 =====
 CPDPRG2 waltz16
 NUC2 1H
 P2 70.00 usec
 PL2 -3.55 dB
 PL12 13.34 dB
 PL13 13.34 dB
 SF02 400.1316005 MHz
 F2 - Processing Parameters
 SI 32768
 SF 100.6127600 MHz
 WTW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 FC 1.40




1D Proton NMR




Current Data Parameters
 NAME J9-0-1edohydrocyclophane-1H
 EXPNO 1
 PROCNO 1
 F2 - Acquisition Parameters
 Date_ 20100416
 Time 10:45
 INSTRUM spect
 PROCNO 17/15
 FULPRG 5930
 ID 65536
 SOLVENT CDCl3
 NS 16
 DS 4
 SWH 8378.146 Hz
 FIDRES 0.124314 Hz
 AQ 3.5584243 sec
 RG 161.3
 DW 60.400 usec
 DE 6.50 usec
 TE 298.0 K
 D1 1.00000000 sec
 D10
 ===== CHANNEL f1 =====
 NUC1 1H
 P1 10.35 usec
 PL1 -2.35 dB
 SF01 400.1324710 MHz
 F2 - Processing Parameters
 SI 32768
 SF 400.1300054 MHz
 EQ EM
 MDW 0
 SSB 0
 LB 0.30 Hz
 GB 0
 EC 1.00






13C

1D Proton NMR





13C



EZ-COSY



Current Data Parameters
 EXPR0 3C-o-methoxyphenylpyrimidin-2b-042918
 PROCNO 1

F2 - Acquisition Parameters

Date_ 20100429
 Time 18.12
 INSTRUM spect
 PULPROG zgpg30
 TD 65536
 SFO 400.130000
 AQ 0.08150000
 RG 1.024
 DM 4.50
 TE 298.0 K
 D0 0.08000000
 D1 0.08000000
 D13 0.08000000
 D15 0.08000000
 D18 0.08000000
 D20 0.08000000

SOLVENT CHANNEL F1

NUC1 13C
 P1 10.00
 PL1 0.00
 P2 10.00
 PL2 0.00
 SFO1 400.1300000 MHz
 GRADIENT CHANNEL
 GPCP1 100
 GPCP2 100
 GPCP3 100

F1 - Acquisition Parameters

TD 128
 SFO1 400.1300000 MHz
 ARES 41.33400000
 P1 10.00
 PL1 0.00

F2 - Processing Parameters

SF 400.1300000 MHz
 MD 32768
 SI 32768
 SF 400.1300000 MHz
 PC 1.00

F1 - Processing Parameters

SI 1024
 SF 400.1300000 MHz
 MD 32768
 SF 400.1300000 MHz
 PC 1.00

